

obeykandl.com

SUMMARY

Summary

Polymeric nanofibers have demonstrated great potential as a platform for many biomedical applications due to their unique properties such as high porosity, strong mechanical properties, , high surface area in addition to their ability for incorporating drugs or bioactive factors for sustained release and localized drug delivery. The combined features of nanofibrous matrices promoted their use for wound healing, anti-tissue adhesion, tissue engineering and other biomedical applications.

Applying the principles of drug delivery technology, we aimed to develop an a novel anti-microbial-loaded nanofibers for the application in various biomedical applications such as promoting healing of infected wounds, prevention or reduction of post-surgical tissue adhesion and development of medicated stents, sutures and other implants. The selected drug was methylene blue that exerts antimicrobial activity that can be enhanced by application of light in what is called Antimicrobial Photodynamic Therapy (APDT) .The current thesis is presented in four chapters.

1. Chapter One: Development of novel methylene blue-loaded polyhydroxybutyrate nanofibers for biomedical applications

This chapter was concerned with the development of methylene blue (MB)-loaded polyhydroxybutyrate (PHB)-based nanofibers that would be used for two different biomedical applications throughout the thesis. The developed fibrous matrices were then examined for their anti-tissue adhesion effect (in Chapter Two). Enhancement of the antimicrobial by the aid of APDT was examined (in Chapter Three) and used (in Chapter Four) as wound dressing for infection control and enhancement of wound healing

Novel MB-loaded PHB-based nanofibers were prepared by emulsion electrospinning with targeted pharmaceutical attributes in terms of drug incorporation efficiency, release pattern and degradability. The effect of experimental variables including: emulsion formulation, polymer concentration and drug loading on morphology, incorporation efficiency and release were investigated. Attempts to modulate the behavior of the developed systems including blending with PEG 4000 were done. The developed nanofibers were characterized by using SEM, DSC, FT-IR, and assessment of drug entrapment efficiency, drug release and polymer degradation. Different formulas have been developed with high incorporation efficiency and average fiber diameter ranging from 400 to 600 nm for the MB loaded ones. Two of them have been selected for further biological applications. They were MB-loaded PHB and PHB/PEG (60/40) nanofibers. They both have high incorporation efficiency almost 100% but they differ in term of hydrophilicity, drug release behavior and matrix degradation. They were designed for two different biomedical applications. As the hydrophilic formula showed a faster initial drug release that could prevent the proliferation of early intruding bacteria, it was tested for its antibacterial activity *in vitro* against 2 bacterial strains; MRSA and *S.aureus*. The effect of the antibacterial nanofibers on bacteria was investigated by viable count technique. The effect of electrospinning on drug antibacterial activity was assessed using the agar diffusion method and proved that MB activity was not affected during the drastic environment of electrospinning.

2. Chapter Two: Tissue anti-adhesion potential of selected polyhydroxybutyrate biomaterials in a rat model

Chapter two was concerned with the investigation of the ability of PHB-based membranes to reduce the post-surgical peritoneal adhesion induced in rat model. MB can induce dual effect for prevention of tissue adhesion through its antimicrobial effect and the direct anti-tissue adhesion effect. So, MB-loaded nanofibers exert a dual effect for reduction of adhesion; as a physical barrier and as a carrier of anti-adhesive pharmacological adjuvant. The formed adhesions were assessed macroscopically through scoring in terms of type, tenacity and extent of adhesion bands formed, and by histological examination. While, the implants retrieved after animal scarification were assessed for changes in their physical properties and microscopically by SEM to examine cell growth and attachment to their surfaces. The results showed a good ability for PHB nanofibers to reduce the formation of adhesion bands, while PHB/PEG blended nanofibers were not recommended for the anti-tissue adhesion application, as the leaching of PEG allows for larger pore formation and cell infiltration; however this property is excellent for tissue engineering scaffold applications. However, it was observed that loading of PHB/PEG nanofibers with MB rendered it able to reduce tissue-adhesion formation. The striking reduction in peritoneal adhesion was obtained by using MB-loaded film. The smooth surface of the film completely prevent cell adherence as examined by SEM. The histological examination of the injured tissue showed a great reduction in inflammation and leukocytes infiltration. That result was further assured by differential WBCs count in peripheral blood that showed neutropenia.

3. Chapter Three : Methylene blue-eluting nanofibers as a potential biomaterial for antimicrobial photodynamic therapy (APDT)

Chapter three aimed to enhance the antibacterial activity of MB-loaded nanofibers by the application of activating red light for APDT. The developed system consisted of the MB-loaded nanofibers and the light of optimum wavelength and fluence were examined for its *in vitro* photobioactivity. Its response to light was assessed by measuring light transmission through the fibrous matrix which showed opaque nature that could protect the encapsulated photosensitizer. For MB to be activated by light, it should be first released from the matrix. The effect of light fluence on singlet oxygen production by the released MB was assessed using uric acid as a quenching agent. Increasing the light fluence up to 300 J/cm^2 would result in more singlet oxygen production which has antibacterial destroying effect. MB-loaded nanofibers were tested for their photodynamic antibacterial activity using red LED at 650 nm which revealed bactericidal activity. Antimicrobial profile of the light activated nanofibers revealed that the tailored MB release profile is well suited with a high initial burst proved to be sufficient for the application of APDT then a slower release rate that did maintain the antibacterial effect of MB in dark.

4. Chapter Four : Methylene blue-eluting nanofibers for antimicrobial photodynamic therapy (APDT) of infected wounds in immunocompromized rats

APDT has an advantage over the traditional treatment by antibiotics, in term of no development of antimicrobial resistance. PHB/PEG nanofibers provide the required properties to enhance wound healing in terms of high hydrophilicity, fluid uptake and good cell

attachment. So, MB-loaded nanofibers would provide a unique dual effect which made it necessary to test it against a challenging model of infected wound. *S. aureus* infected wounds were induced in cyclosporine A- immunosuppressed rat model. Wounds were irradiated with red LED at 650 nm after eluting a suitable amount of MB from the fibrous mats. The wound healing properties of MB-loaded PHB/PEG nanofibers was assessed by microbiological and morphological examination. Application of MB-loaded nanofibers with multiple irradiation resulted in accelerated wound healing of better quality and no scar formation on the macroscopic scale. The results are due to enhanced re-epithelization and granular tissue formation as revealed by histological examination. APDT has also succeeded to eradicate the infective bacteria. At the molecular level, examination of VEGF, PDGF, COX-2 and TNF- α levels by RT-PCR showed a great potential of MB-loaded PHB/PEG NFs combined with APDT to enhance wound healing.

REFERENCES

References

1. Nair, L.S. and C.T. Laurencin, *Biodegradable polymers as biomaterials*. Prog Polym Sci, 2007. **32**(8–9): p. 762-798.
2. Vogelson, C.T., *Advances in drug delivery systems: Innovative pharmaceutical treatments require innovative methods of administration*. Mod Drug Discovery, 2001. **4**(4): p. 49-50.
3. Pillai, O. and R. Panchagnula, *Polymers in drug delivery*. Curr Opin Chem Biol, 2001. **5**(4): p. 447-451.
4. Zhang, Y., et al., *Recent development of polymer nanofibers for biomedical and biotechnological applications*. J Mater Sci Mater Med, 2005. **16**(10): p. 933-946.
5. Chew, S.Y. and T.G. Park, *Nanofibers in regenerative medicine and drug delivery*. Adv Drug Deliv Rev, 2009. **61**(12): p. 987.
6. Choi, J.S., K.W. Leong, and H.S. Yoo, *In vivo wound healing of diabetic ulcers using electrospun nanofibers immobilized with human epidermal growth factor (EGF)*. Biomaterials, 2008. **29**(5): p. 587-596.
7. Huang, Z.-M., et al., *A review on polymer nanofibers by electrospinning and their applications in nanocomposites*. Compos Sci Technol, 2003. **63**(15): p. 2223-2253.
8. Theron, J., J.A. Walker, and T.E. Cloete, *Nanotechnology and Water Treatment: Applications and Emerging Opportunities*. Crit Rev Microbiol, 2008. **34**(1): p. 43-69.
9. Fang, J., et al., *Applications of electrospun nanofibers*. Chinese Science Bulletin, 2008. **53**(15): p. 2265-2286.
10. Chew, S.Y., et al., *Sustained Release of Proteins from Electrospun Biodegradable Fibers*. Biomacromolecules, 2005. **6**(4): p. 2017-2024.
11. Kenawy, E.-R., et al., *Release of tetracycline hydrochloride from electrospun poly(ethylene-co-vinylacetate), poly(lactic acid), and a blend*. J Control Release, 2002. **81**(1–2): p. 57-64.
12. Vasita, R. and D.S. Katti, *Nanofibers and their applications in tissue engineering*. Int J Nanomedicine, 2006. **1** (1): p. 15–30.
13. El-Newehy, M.H., et al., *Nanospider Technology for the Production of Nylon-6 Nanofibers for Biomedical Applications*. J Nanomater, 2011. **2011**.
14. Lu, B., et al., *A new ultrahigh-speed method for the preparation of nanofibers containing living cells: A bridge towards industrial bioengineering applications*. Nanoscale, 2012. **4**(3): p. 1003-1009.
15. Jayaraman, K., et al., *Recent advances in polymer nanofibers*. J Nanosci Nanotechnol., 2004. **4**(1-2): p. 52-65.
16. Cooley, J.F., *Apparatus for electrically dispersing fluids*. 1902: USA.
17. Formhals, A., *Method and apparatus for spinning*. 1939.
18. Taylor, G., *Electrically driven jets*. Proceedings of the Royal Society of London. Series A, Mathematical and Physical Sciences, 1969. **313**(1515): p. 453-475.
19. Reneker, D.H. and J. Doshi, *Electrospinning process and applications of electrospun fibers*. Journal of Electrostatics, 1995. **35**(2-3): p. 151– 160.
20. Reneker, D.H., et al., *Bending instability of electrically charged liquid jets of polymer solutions in electrospinning*. Journal of Applied Physics, 2000. **87**(9): p. 4531-4547.
21. Heunis, T.D.J. and L.M.T. Dicks, *Nanofibers Offer Alternative Ways to the Treatment of Skin Infections*. J Biomed Biotechnol, 2010. **2010**.
22. Bhardwaj, N. and S.C. Kundu, *Electrospinning: A fascinating fiber fabrication technique*. Biotechnol Adv, 2010. **28**(3): p. 325-347.

23. Yarin, A.L., S. Koombhongse, and D.H. Reneker, *Taylor cone and jetting from liquid droplets in electrospinning of nanofibers*. J Appl Phys, 2001. **90**(9): p. 4836-4846.
24. Baji, A., et al., *Electrospinning of polymer nanofibers: Effects on oriented morphology, structures and tensile properties*. Compos Sci Technol, 2010. **70**(5): p. 703-718.
25. Yarin, A.L., S. Koombhongse, and D.H. Reneker, *Bending instability in electrospinning of nanofibers* Journal of Applied Physics, 2001. **89**(5): p. 3018-3026.
26. Y.M. Shin, M.M.H., M.P. Brenner, G.C. Rutledge, *Experimental characterization of electrospinning: the electrically forced jet and instabilities*. Polymer, 2001. **42**(25): p. 09955-09967.
27. Subbiah, T., et al., *Electrospinning of nanofibers*. Journal of Applied Polymer Science, 2005. **96**(2): p. 557-569.
28. Verreck, G., et al., *Incorporation of drugs in an amorphous state into electrospun nanofibers composed of a water-insoluble, nonbiodegradable polymer*. J Control Release, 2003. **92**(3): p. 349-360.
29. Zeng, J., et al., *Influence of the drug compatibility with polymer solution on the release kinetics of electrospun fiber formulation*. J Control Release, 2005. **105**(1-2): p. 43-51.
30. Kim, K., et al., *Incorporation and controlled release of a hydrophilic antibiotic using poly(lactide-co-glycolide)-based electrospun nanofibrous scaffolds*. J Control Release, 2004. **98**(1): p. 47-56.
31. Innocente, F., et al., *Paclitaxel-Eluting Biodegradable Synthetic Vascular Prostheses*. Circulation, 2009. **120**(11 suppl 1): p. S37-S45.
32. Luu, Y.K., et al., *Development of a nanostructured DNA delivery scaffold via electrospinning of PLGA and PLA-PEG block copolymers*. J Control Release, 2003. **89**(2): p. 341-353.
33. Luong-Van, E., et al., *Controlled release of heparin from poly(ϵ -caprolactone) electrospun fibers*. Biomaterials, 2006. **27**(9): p. 2042-2050.
34. Zeng, J., et al., *Poly(vinyl alcohol) Nanofibers by Electrospinning as a Protein Delivery System and the Retardation of Enzyme Release by Additional Polymer Coatings*. Biomacromolecules, 2005. **6**(3): p. 1484-1488.
35. Szentivanyi, A., et al., *Production of biohybrid protein/PEO scaffolds by electrospinning*. Materwiss Werksttech, 2009. **40**(1-2): p. 65-72.
36. Chong, E.J., et al., *Evaluation of electrospun PCL/gelatin nanofibrous scaffold for wound healing and layered dermal reconstitution*. Acta Biomater, 2007. **3**(3): p. 321-330.
37. Li, D. and Y. Xia, *Electrospinning of Nanofibers: Reinventing the Wheel?* Adv Mater, 2004. **16**(14): p. 1151-1170.
38. Sill, T.J. and H.A. von Recum, *Electrospinning: Applications in drug delivery and tissue engineering*. Biomaterials, 2008. **29**(13): p. 1989-2006.
39. Zhong, S., et al., *An aligned nanofibrous collagen scaffold by electrospinning and its effects on in vitro fibroblast culture*. J Biomed Mater Res A, 2006. **79A**(3): p. 456-463.
40. Li, J., et al., *Gelatin and Gelatin-Hyaluronic Acid Nanofibrous Membranes Produced by Electrospinning of Their Aqueous Solutions*. Biomacromolecules, 2006. **7**(7): p. 2243-2247.
41. Li, M., et al., *Electrospun protein fibers as matrices for tissue engineering*. Biomaterials, 2005. **26**(30): p. 5999-6008.

42. Wang, X., et al., *Formation of water-resistant hyaluronic acid nanofibers by blowing-assisted electro-spinning and non-toxic post treatments*. *Polymer*, 2005. **46**(13): p. 4853-4867.
43. Zhou, Y., et al., *Electrospun Water-Soluble Carboxyethyl Chitosan/Poly(vinyl alcohol) Nanofibrous Membrane as Potential Wound Dressing for Skin Regeneration*. *Biomacromolecules*, 2007. **9**(1): p. 349-354.
44. Son, W.K., J.H. Youk, and W.H. Park, *Antimicrobial cellulose acetate nanofibers containing silver nanoparticles*. *Carbohydr Polym*, 2006. **65**(4): p. 430-434.
45. Fang, X. and D.H. Reneker, *DNA fibers by electrospinning*. *Journal of Macromolecular Science, Part B*, 1997. **36**(2): p. 169-173.
46. Said, S.S., et al., *Antimicrobial PLGA ultrafine fibers: Interaction with wound bacteria*. *Eur J Pharm Biopharm*, 2011. **79**(1): p. 108-118.
47. Bölgen, N., et al., *In vivo performance of antibiotic embedded electrospun PCL membranes for prevention of abdominal adhesions*. *J Biomed Mater Res B Appl Biomater*, 2007. **81B**(2): p. 530-543.
48. Mosinger, J., et al., *Photofunctional Polyurethane Nanofabrics Doped by Zinc Tetraphenylporphyrin and Zinc Phthalocyanine Photosensitizers*. *J Fluoresc*, 2009. **19**(4): p. 705-713.
49. Yang, D.-J., et al., *Tissue anti-adhesion potential of biodegradable PELA electrospun membranes*. *Acta Biomater*, 2009. **5**(7): p. 2467-2474.
50. Han, I., et al., *Effect of Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) Nanofiber Matrices Cocultured With Hair Follicular Epithelial and Dermal Cells for Biological Wound Dressing*. *Artif Organs*, 2007. **31**(11): p. 801-808.
51. Bonino, C.A., et al., *Electrospinning alginate-based nanofibers: From blends to crosslinked low molecular weight alginate-only systems*. *Carbohydr Polym*, 2011. **85**(1): p. 111-119.
52. Szentivanyi, A., et al., *Electrospun cellular microenvironments: Understanding controlled release and scaffold structure*. *Adv Drug Deliv Rev*, 2011. **63**(4-5): p. 209-220.
53. Chakraborty, S., et al., *Electrohydrodynamics: A facile technique to fabricate drug delivery systems*. *Adv Drug Deliv Rev*, 2009. **61**(12): p. 1043-1054.
54. He, C.L., et al., *Coaxial Electrospun Poly(L-Lactic Acid) Ultrafine Fibers for Sustained Drug Delivery*. *Journal of Macromolecular Science, Part B*, 2006. **45**(4): p. 515-524.
55. Kowalczyk, T., et al., *Electrospinning of Bovine Serum Albumin. Optimization and the Use for Production of Biosensors*. *Biomacromolecules*, 2008. **9**(7): p. 2087-2090.
56. Jiang, H., et al., *Modulation of protein release from biodegradable core-shell structured fibers prepared by coaxial electrospinning*. *J Biomed Mater Res B Appl Biomater*, 2006. **79B**(1): p. 50-57.
57. Li, Y., H. Jiang, and K. Zhu, *Encapsulation and controlled release of lysozyme from electrospun poly(ϵ -caprolactone)/poly(ethylene glycol) non-woven membranes by formation of lysozyme-oleate complexes*. *J Mater Sci Mater Med*, 2008. **19**(2): p. 827-832.
58. Ji, W., et al., *Fibrous scaffolds loaded with protein prepared by blend or coaxial electrospinning*. *Acta Biomater*, 2010. **6**(11): p. 4199-4207.
59. Xu, X., et al., *The release behavior of doxorubicin hydrochloride from medicated fibers prepared by emulsion-electrospinning*. *Eur J Pharm Biopharm*, 2008. **70**(1): p. 165-170.

60. Xu, X., et al., *Ultrafine PEG–PLA fibers loaded with both paclitaxel and doxorubicin hydrochloride and their in vitro cytotoxicity*. Eur J Pharm Biopharm, 2009. **72**(1): p. 18-25.
61. Yang, Y., et al., *Structural stability and release profiles of proteins from core-shell poly (DL-lactide) ultrafine fibers prepared by emulsion electrospinning*. J Biomed Mater Res A, 2008. **86A**(2): p. 374-385.
62. Li, X., et al., *Encapsulation of proteins in poly(l-lactide-co-caprolactone) fibers by emulsion electrospinning*. Colloids Surf B Biointerfaces, 2010. **75**(2): p. 418-424.
63. Yan, S., et al., *Controlled release of dual drugs from emulsion electrospun nanofibrous mats*. Colloids Surf B Biointerfaces, 2009. **73**(2): p. 376-381.
64. Xu, X., et al., *Ultrafine medicated fibers electrospun from W/O emulsions*. J Control Release, 2005. **108**(1): p. 33-42.
65. Sy, J.C., A.S. Klemm, and V.P. Shastri, *Emulsion as a Means of Controlling Electrospinning of Polymers*. Adv Mater, 2009. **21**(18): p. 1814-1819.
66. Venugopal, G., S. Krause, and G.E. Wnek, *Morphological variations in polymer blends made in electric fields*. Chem Mater, 1992. **4**(6): p. 1334-1343.
67. Yarin, A.L., *Coaxial electrospinning and emulsion electrospinning of core-shell fibers*. Polym Adv Technol, 2011. **22**: p. 310-317.
68. Qi, et al., *Encapsulation of Drug Reservoirs in Fibers by Emulsion Electrospinning: Morphology Characterization and Preliminary Release Assessment*. Biomacromolecules, 2006. **7**(8): p. 2327-2330.
69. Xu, X., et al., *Preparation of Core-Sheath Composite Nanofibers by Emulsion Electrospinning*. Macromol Rapid Commun, 2006. **27**(19): p. 1637-1642.
70. Feng, C., et al., *Preparation and characterization of electro-spun nanofiber membranes and their possible applications in water treatment*. Separation and Purification Technology, 2013. **102**(0): p. 118-135.
71. Yu, D.-G., et al., *Electrospun nanofiber-based drug delivery systems*. Health, 2009. **1**(2): p. 67-75.
72. Liao, I.C., S.Y. Chew, and K.W. Leong, *Aligned core-shell nanofibers delivering bioactive proteins*. Nanomedicine, 2006. **1**(4): p. 465-471.
73. Yoo, H.S., T.G. Kim, and T.G. Park, *Surface-functionalized electrospun nanofibers for tissue engineering and drug delivery*. Adv Drug Deliv Rev, 2009. **61**(12): p. 1033-1042.
74. Dong, H., et al., *Assembly of Metal Nanoparticles on Electrospun Nylon 6 Nanofibers by Control of Interfacial Hydrogen-Bonding Interactions*. Chem Mater, 2008. **20**(21): p. 6627-6632.
75. Taylor, G.D., et al., *Predominance of staphylococcal organisms in infections occurring in a burns intensive care unit*. Burns, 1992. **18**(4): p. 332-335.
76. Kim, J., *Understanding the Evolution of Methicillin-Resistant Staphylococcus aureus*. Clinical Microbiology Newsletter, 2009. **31**(3): p. 17-23.
77. Fraise, A.P., et al., *Methicillin-resistant Staphylococcus aureus (MRSA) in nursing homes in a major UK city: an anonymized point prevalence survey*. Epidemiol Infect., 1997. **118**(1): p. 1-5.
78. Zapun, A., C. Contreras-Martel, and T. Vernet, *Penicillin-binding proteins and β -lactam resistance*. FEMS Microbiol Rev, 2008. **32**(2): p. 361-385.
79. Costerton, J.W., P.S. Stewart, and E.P. Greenberg, *Bacterial Biofilms: A Common Cause of Persistent Infections*. Science, 1999. **284**(5418): p. 1318-1322.
80. Church, D., et al., *Burn wound infections*. Clin. Microbiol. Rev., 2006 **19**(2): p. 403-434.

81. Madkour, A.E. and G.N. Tew, *Towards self-sterilizing medical devices: controlling infection*. Polym. Int, 2008. **57**(1): p. 6-10.
82. Klibanov, A.M., *Permanently microbicidal materials coatings*. J Mater Chem, 2007. **17**(24): p. 2479-2482.
83. Moon, W.-S., et al., *Antimicrobial activity of a monomer and its polymer based on quinolone*. J Appl Polym Sci, 2003. **90**(7): p. 1797-1801.
84. Ignatova, M., N. Manolova, and I. Rashkov, *Electrospinning of poly(vinyl pyrrolidone)–iodine complex and poly(ethylene oxide)/poly(vinyl pyrrolidone)–iodine complex – a prospective route to antimicrobial wound dressing materials*. Eur Polym J, 2007. **43**(5): p. 1609-1623.
85. Ignatova, M., et al., *Antibacterial and antimycotic activity of a cross-linked electrospun poly(vinyl pyrrolidone)–iodine complex and a poly(ethylene oxide)/poly(vinyl pyrrolidone)–iodine complex*. J Biomater Sci Polym Ed, 2008. **19**(3): p. 373-386.
86. Ignatova, M., N. Manolova, and I. Rashkov, *Novel antibacterial fibers of quaternized chitosan and poly(vinyl pyrrolidone) prepared by electrospinning*. Eur Polym J, 2007. **43**(4): p. 1112-1122.
87. Qun, X.L., et al., *Antibacterial Nanofibers of Self-quaternized Block Copolymers of 4-Vinyl Pyridine and Pentachlorophenyl Acrylate* High Perform. Polym, 2010. **22**: p. 359–376.
88. Ladaviere, C., et al., *Covalent immobilization of biological molecules to maleic anhydride and methyl vinyl ether copolymers—A physico-chemical approach*. J Appl Polym Sci, 1999. **71**(6): p. 927-936.
89. Patel, H., et al., *Polymeric prodrug: Synthesis, release study and antimicrobial property of poly(styrene-co-maleic anhydride)-bound acriflavine*. Die Angewandte Makromolekulare Chemie, 1998. **263**(1): p. 25-30.
90. Patel, H., et al., *Polymeric prodrugs. Synthesis, release study and antimicrobial properties of polymer-bound acriflavine*. Die Angewandte Makromolekulare Chemie, 1997. **245**(1): p. 1-8.
91. Patel, J.S., et al., *Bioactive polymers: Synthesis, release study and antimicrobial properties of polymer bound Ampicillin*. Die Angewandte Makromolekulare Chemie, 1999. **271**(1): p. 24-27.
92. Rinaudo, M., *Chitin and chitosan: Properties and applications*. Prog Polym Sci, 2006. **31**(7): p. 603-632.
93. Lim, S.-H. and S.M. Hudson, *Review of Chitosan and Its Derivatives as Antimicrobial Agents and Their Uses as Textile Chemicals*. J Macromol Sci, Part C, 2003. **43**(2): p. 223-269.
94. Pillai, C.K.S., W. Paul, and C.P. Sharma, *Chitin and chitosan polymers: Chemistry, solubility and fiber formation*. Prog Polym Sci, 2009. **34**(7): p. 641-678.
95. Shin, Y., D.I. Yoo, and J. Jang, *Molecular weight effect on antimicrobial activity of chitosan treated cotton fabrics*. J Appl Polym Sci, 2001. **80**(13): p. 2495-2501.
96. Kean, T. and M. Thanou, *Biodegradation, biodistribution and toxicity of chitosan*. Adv Drug Deliv Rev, 2010. **62**(1): p. 3-11.
97. Jarmila, V. and E. Vavříková, *Chitosan derivatives with antimicrobial, antitumour and antioxidant activities--a review*. Curr Pharm Des., 2011. **17**(32): p. 3596-607.
98. Torres-Giner, S., M.J. Ocio, and J.M. Lagaron, *Development of Active Antimicrobial Fiber-Based Chitosan Polysaccharide Nanostructures using Electrospinning*. Engineering in Life Sciences, 2008. **8**(3): p. 303-314.

99. Ignatova, M., et al., *Electrospun nano-fibre mats with antibacterial properties from quaternised chitosan and poly(vinyl alcohol)*. Carbohydr Res, 2006. **341**(12): p. 2098-2107.
100. Pavinatto, A., et al., *Electrostatic Interactions Are Not Sufficient to Account for Chitosan Bioactivity*. ACS Appl Mater Interfaces, 2009. **2**(1): p. 246-251.
101. Son, B., et al., *Antibacterial electrospun chitosan/poly(vinyl alcohol) nanofibers containing silver nitrate and titanium dioxide*. J Appl Polym Sci, 2009. **111**(6): p. 2892-2899.
102. Torres-Giner, S., M.J. Ocio, and J.M. Lagaron, *Novel antimicrobial ultrathin structures of zein/chitosan blends obtained by electrospinning*. Carbohydr Polym, 2009. **77**(2): p. 261-266.
103. Leung, V., et al., *Bioactive Nanofibres for Wound Healing Applications*. Journal of Fiber Bioengineering & Informatics 2011. **1-14**(1).
104. Liu, H., K.K. Leonas, and Y. Zhao, *Antimicrobial Properties and Release Profile of Ampicillin from Electrospun Poly(ϵ -caprolactone) Nanofiber Yarns* J Eng Fiber Fabr, 2010. **5**(4): p. 10-19.
105. Xu, X., et al., *Electrospun PEG-PLA nanofibrous membrane for sustained release of hydrophilic antibiotics*. J Appl Polym Sci, 2010. **118**(1): p. 588-595.
106. Thakur, R.A., et al., *Electrospun nanofibrous polymeric scaffold with targeted drug release profiles for potential application as wound dressing*. Int J Pharm, 2008. **364**(1): p. 87-93.
107. Jack, R.W., J.R. Tagg, and B. Ray, *Bacteriocins of gram-positive bacteria*. Microbiol Rev., 1995 **59**(2): p. 171-200.
108. Moll, G.N., W.N. Konings, and A.J.M. Driessen, *Bacteriocins: mechanism of membrane insertion and pore formation*. Antonie van Leeuwenhoek, 1999. **76**(1): p. 185-198.
109. McAuliffe, O., R.P. Ross, and C. Hill, *Lantibiotics: structure, biosynthesis and mode of action*. FEMS Microbiol Rev, 2001. **25**(3): p. 285-308.
110. Heunis, T., M. Botes, and L. Dicks, *Encapsulation of Lactobacillus plantarum 423 and its Bacteriocin in Nanofibers*. Probiotics Antimicrob Proteins, 2010. **2**(1): p. 46-51.
111. Botes, M. and T. Eugene Cloete, *The potential of nanofibers and nanobiocides in water purification*. Crit Rev Microbiol, 2010. **36**(1): p. 68-81.
112. Melaiye, A. and W.J. Youngs, *Silver and its application as an antimicrobial agent*. Expert Opin Ther Pat, 2005. **15**(2): p. 125-130.
113. Lala, N.L., et al., *Fabrication of nanofibers with antimicrobial functionality used as filters: protection against bacterial contaminants*. Biotechnol Bioeng, 2007. **97**(6): p. 1357-1365.
114. Teo, W.-E. and S. Ramakrishna, *Electrospun nanofibers as a platform for multifunctional, hierarchically organized nanocomposite*. Compos Sci Technol, 2009. **69**(11-12): p. 1804-1817.
115. Hong, K.H., et al., *Preparation of antimicrobial poly(vinyl alcohol) nanofibers containing silver nanoparticles*. J Polym Sci, Part B: Polym Phys, 2006. **44**(17): p. 2468-2474.
116. Rujitanaroj, P.-o., N. Pimpha, and P. Supaphol, *Wound-dressing materials with antibacterial activity from electrospun gelatin fiber mats containing silver nanoparticles*. Polymer, 2008. **49**(21): p. 4723-4732.
117. Duan, Y.-y., et al., *Preparation of antimicrobial poly(ϵ -caprolactone) electrospun nanofibers containing silver-loaded zirconium phosphate nanoparticles*. J Appl Polym Sci Symp, 2007. **106**(2): p. 1208-1214.

118. AshaRani, P.V., et al., *Cytotoxicity and Genotoxicity of Silver Nanoparticles in Human Cells*. ACS Nano, 2008. **3**(2): p. 279-290.
119. Kong, H., J. Song, and J. Jang, *Photocatalytic antibacterial capabilities of TiO₂-biocidal polymer nanocomposites synthesized by a surface-initiated photopolymerization*. Environmental science & technology, 2010. **44**(14): p. 5672-5676.
120. Azad, A.-M., S.L. McKelvey, and Z. Al-Firdaus, *Fabrication of antimicrobial titania nanofibers by electrospinning*. The AMMTIAC Quarterly. **3**(3): p. 3-7.
121. Azad, A.-M., et al., *Bactericidal efficacy of electrospun pure and Fe-doped titania nanofibers*. Mater Res, 2010. **25**(9): p. 1761-1770.
122. Sheikh, F., et al., *Electrospun titanium dioxide nanofibers containing hydroxyapatite and silver nanoparticles as future implant materials*. J Mater Sci Mater Med, 2010. **21**(9): p. 2551-2559.
123. Chen, F., C.N. Lee, and S.H. Teoh, *Nanofibrous modification on ultra-thin poly(ϵ -caprolactone) membrane via electrospinning*. Mater Sci Eng, C, 2007. **27**(2): p. 325-332.
124. Murugan, R. and S. Ramakrishna, *Nano-featured scaffolds for tissue engineering: A review of spinning methodologies*. Tissue Eng, 2006. **12**(3): p. 435-447.
125. Sing Yian, C., et al., *Mechanical properties of single electrospun drug-encapsulated nanofibres*. Nanotechnology, 2006. **17**(15): p. 3880.
126. Liang, D., B.S. Hsiao, and B. Chu, *Functional electrospun nanofibrous scaffolds for biomedical applications*. Adv Drug Deliv Rev, 2007. **59**(14): p. 1392-1412.
127. Ruckh, T., et al., *Antimicrobial effects of nanofiber poly(ϵ -caprolactone) tissue scaffolds releasing rifampicin*. J Mater Sci Mater Med, 2012. **23**(6): p. 1411-1420.
128. Liakakos, T., et al., *Peritoneal Adhesions: Etiology, Pathophysiology, and Clinical Significance*. Dig Surg, 2001. **18**(4): p. 260-273.
129. Boland, G.M. and R.J. Weigel, *Formation and Prevention of Postoperative Abdominal Adhesions*. J Surg Res, 2006. **132**(1): p. 3-12.
130. Dinarvand, P., et al., *Function of Poly (lactic-co-glycolic acid) Nanofiber in Reduction of Adhesion Bands*. J Surg Res, 2012. **172**(1): p. e1-e9.
131. Zong, X., et al., *Prevention of Postsurgery-Induced Abdominal Adhesions by Electrospun Bioabsorbable Nanofibrous Poly(lactide-co-glycolide)-Based Membranes*. Ann Surg, 2004. **240**(5): p. 910-915.
132. Chang, J.-J., et al., *Electrospun anti-adhesion barrier made of chitosan alginate for reducing peritoneal adhesions*. Carbohydr Polym, 2012. **88**(4): p. 1304-1312.
133. Dai, Z.-W., X.-H. Zou, and G.-Q. Chen, *Poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) as an injectable implant system for prevention of post-surgical tissue adhesion*. Biomaterials, 2009. **30**(17): p. 3075-3083.
134. Lazarus Gs, C.D.M.K.D.R. and et al., *DEfinitions and guidelines for assessment of wounds and evaluation of healing*. Arch Dermatol, 1994. **130**(4): p. 489-493.
135. Strodbeck, F., *Physiology of wound healing*. Newborn Infant Nurs Rev, 2001. **1**(1): p. 43-52.
136. Russell, L., *Understanding physiology of wound healing and how dressings help*. Br J Nurs., 2000 **9**(1): p. 10-21.
137. Boateng, J.S., et al., *Wound healing dressings and drug delivery systems: A review*. J Pharm Sci, 2008. **97**(8): p. 2892-2923.
138. Zahedi, P., et al., *A review on wound dressings with an emphasis on electrospun nanofibrous polymeric bandages*. Polym Adv Technol, 2010. **21**(2): p. 77-95.
139. Roh, D.-H., et al., *Wound healing effect of silk fibroin/alginate-blended sponge in full thickness skin defect of rat*. J Mater Sci Mater Med, 2006. **17**(6): p. 547-552.

140. Cai, Z.-x., et al., *Fabrication of Chitosan/Silk Fibroin Composite Nanofibers for Wound-dressing Applications*. Int J Mol Sci., 2010. **11**(9): p. 3529–3539.
141. Chen, J.-P., G.-Y. Chang, and J.-K. Chen, *Electrospun collagen/chitosan nanofibrous membrane as wound dressing*. Colloids Surf A Physicochem Eng Asp, 2008. **313–314**(0): p. 183-188.
142. Chen, R.-N., et al., *Development of N,O-(Carboxymethyl)chitosan/Collagen Matrixes as a Wound Dressing*. Biomacromolecules, 2006. **7**(4): p. 1058-1064.
143. Duan, Y.-y., et al., *Preparation of antimicrobial poly(ϵ -caprolactone) electrospun nanofibers containing silver-loaded zirconium phosphate nanoparticles*. J Appl Polym Sci, 2007. **106**(2): p. 1208-1214.
144. Liu, S.-J., et al., *Electrospun PLGA/collagen nanofibrous membrane as early-stage wound dressing*. J Memb Sci, 2010. **355**(1–2): p. 53-59.
145. Ochsner, M., *Photophysical and photobiological processes in the photodynamic therapy of tumours*. J Photochem Photobiol B, 1997. **39**: p. 1–18.
146. Maisch, T., *Anti-microbial photodynamic therapy: useful in the future?* Lasers Med Sci, 2007. **22**: p. 83–91.
147. Moan, J. and Q.P. . *An outline of the hundred-year history of PDT*. Anticancer Res, 2003. **23**(5A): p. 3591-600.
148. Ackroyd, R., C. Kelty, and N. Brown, *The History of Photodetection and Photodynamic Therapy*. Photochem Photobiol, 2001. **74**(5): p. 656–669.
149. Bell, S.G., *Antibiotic resistance: is the end of an era near?* Neonatal Netw, 2003 **22**(6): p. 47-54.
150. Dougherty, T.J., *An Update on Photodynamic Therapy Applications*. J Clin Laser Med Surg, 2002. **20**(1): p. 3-7.
151. Lukšienė, Ž., *Photodynamic therapy: mechanism of action and ways to improve the efficiency of treatment*. Medicina 2003. **39**(12): p. 1137-50.
152. Wilson, B.C., *Advanced Photodynamic Therapy*, in *Biological and Medical Physics, Biomedical Engineering " Biophotonics"*, L. Pavesi and P.M. Fauchet, Editors. 2008.
153. Nishiyama, A.N., D.Y. Morimoto, and E.W.D. Jang, *Design and development of dendrimer photosensitizer-incorporated polymeric micelles for enhanced photodynamic therapy*. Adv Drug Deliv Rev, 2009. **61** p. 327–338.
154. Moan, J. and K. Berg, *The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen*. Photochem Photobiol, 1991. **53**: p. 549-553
155. Wöhrle, D., A. Hirth, and T. Bogdahn-Rai, *Photodynamic therapy of cancer: Second and third generations of photosensitizers*. Russ Chem Bull, 1998. **47**: p. 807-816.
156. Moan, J. and Q. Peng, *An outline of the hundred-year history of PDT,*". Anticancer Research, 2003. **23**: p. 3591–3600.
157. Wainwright, M., *Photodynamic antimicrobial chemotherapy (PACT)*. J Antimicrob Chemother, 1998. **42**: p. 13-28.
158. DeRosa, M.C. and R.J. Crutchley, *Photosensitized singlet oxygen and its applications*. Coord Chem Rev, 2002. **233–234**: p. 351–371.
159. Wang, K.-K., K.-H. Choi, and H.-W. Shin, *Photophysics of a new photosensitizer with high quantum yield of singlet oxygen generation and its application to stereo-selective synthesis of (+)-deoxoartemisinin*. Chem Phys Lett, 2009. **482**: p. 81–86.
160. Phoenix, D.A. and F. Harris, *Phenothiazinium-based photosensitizers: antibacterials of the future?* Trends Mol Med 2003. **9**(7): p. 283-285.
161. Wainwright, M., *The development of phenothiazinium photosensitisers*. Photodiagnosis Photodyn Ther, 2005. **2**(4): p. 263-272.

162. Jori, G., C. Fabris, and M. Soncin, *Photodynamic therapy in the treatment of microbial infections: Basic principles and perspective applications*. Lasers Surg Med 2006. **38**.
163. Phoenix, D.A., et al., *The phototoxicity of phenothiazinium derivatives against Escherichia coli and Staphylococcus aureus*. FEMS Immunol Med Microbiol 2003. **39**(1): p. 17-22.
164. Wainwright, M., *Methylene blue derivatives — suitable photoantimicrobials for blood product disinfection?* Int J Antimicrob Agents 2000. **16**(4): p. 381-394.
165. Bonnett, R. and M. Berenbaum, in *Porphyrins as photosensitizers*, G. Bock and S. Harnett, Editors. 1989, John Wiley & Sons Ltd: Chichester, UK. p. 40-59
166. Lier, J.E.v. and J.D. Spikes, in *The chemistry, photophysics and photosensitizing properties of phthalocyanines*, G. Bock and S. Harnett, Editors. 1989, John Wiley & Sons Ltd: Chichester, UK. p. 17-32.
167. Ledo, E. and A. Ledo, *Phototherapy, photochemotherapy, and photodynamic therapy: unapproved uses or indications*. Clin Dermatol 2000. **18**(1): p. 77-86.
168. Wainwright, M., *Photoinactivation of viruses*. Photochem Photobiol Sci 2004. **3**: p. 406-411.
169. Calin, M.A. and S.V. Parasca, *Photodynamic therapy in oncology*. J Optoelectron Adv M, 2006. **8**: p. 1173 - 1179.
170. Szeimies, R.-M., S. Karrer, and C. Abels, *Photodynamic Therapy in Dermatology*, in *Dermatological Phototherapy and Photodiagnostic Methods*, J. Krutmann, Editor. 2001.
171. Wennberg, A.M., et al., *Treatment of superficial basal cell carcinomas using topically applied delta-aminolaevulinic acid and a filtered xenon lamp*. Arch Dermatol Res, 1996 **288**(10): p. 561-4.
172. Waldow, S.M., B.W. Henderson, and T.J. Dougherty, *Hyperthermic potentiation of photodynamic therapy employing Photofrin I and II: comparison of results using three animal tumor models*. Lasers Surg Med, 1987. **7**(1): p. 12-22.
173. Wilson, B.C., *Light sources for photodynamic therapy*. Photodynamics News 1998. **1**: p. 6-8.
174. Plaetzer, K., et al., *Photophysics and photochemistry of photodynamic therapy: fundamental aspects*. Lasers Med Sci, 2009. **24**(2): p. 259-268.
175. Kalka, K., H. Merk, and H. Mukhtar, *Photodynamic therapy in dermatology*. J Am Acad Dermatol, 2000 **42**: p. 389-413.
176. Dai, T., Y. Huang, and M. Hamblin, *Photodynamic therapy for localized infections--state of the art*. Photodiagn Photodyn Ther 2009. **6**: p. 170-188.
177. Biel, M.A., *Photodynamic therapy of bacterial and fungal biofilm infections*. Methods Mol Biol., 2010. **635**: p. 175-94.
178. Lambrechts, S.A.G., et al., *Photodynamic therapy for Staphylococcus aureus infected burn wounds in mice*. Photochem Photobiol Sci, 2005. **4**(7): p. 503-509.
179. Orenstein, A., et al., *The use of porphyrins for eradication of Staphylococcus aureus in burn wound infections*. FEMS Immunol Med Microbiol, 1997. **19**(4): p. 307-314.
180. Teichert, M., J. Jones, and M. Biel, *Treatment of oral candidiasis with methylene blue-mediated photodynamic therapy in an immunodeficient murine model*. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2002. **93**: p. 155-160.
181. Sohl, S., F. Kauer, and J.S. . *Photodynamic treatment of cutaneous leishmaniasis*. J Dtsch Dermatol Ges 2007. **5**: p. 128-130.
182. Mohr, H., J. Knuver-Hopf, and T. Muller, *West Nile virus in plasma is highly sensitive to methylene blue-light treatment*. Transfusion 2004. **44**: p. 886-890.

183. Friedrich, C., D. Moyles, and R. Hancock, *Antibacterial action of structurally diverse cationic peptides on Gram-positive bacteria*. . Antimicrob Agents Chemother, 2000. **44**: p. 2086–2092.
184. Nikaido, H., *Prevention of drug access to bacterial targets: Permeability barrier and active efflux*. Science 1994. **264**: p. 362–368.
185. Malik, Z., H. Ladan, and Y. Nitzan, *Photodynamic inactivation of Gram-negative bacteria: Problems and possible solutions*. J Photochem Photobiol B: Biol 1992. **14**: p. 262–266.
186. George, S., M.R. Hamblin, and A. Kishen, *Uptake pathways of anionic and cationic photosensitizers into bacteria*. Photochem Photobiol Sci, 2009. **8**(6): p. 788-795.
187. Bertoloni G, R.F., Valduga G, Jori G, Ali H and van Lier JE., *Photosensitising activity of water- and lipid-soluble phthalocyanines on prokaryotic and eukaryotic microbial cells*. Microbios 1992. **71**: p. 33–46.
188. Hamblin, M.R., et al., *Polycationic photosensitizer conjugates: effects of chain length and Gram classification on the photodynamic inactivation of bacteria*. J Antimicrob Chemother, 2002. **49**(6): p. 941-951.
189. Demidova, T. and M. Hamblin, *Photodynamic therapy targeted to pathogens*. Int J Immunopathol Pharmacol 2004. **17**: p. 245-254.
190. Soenen, S.J.H., A.R. Brisson, and M. De Cuyper, *Addressing the problem of cationic lipid-mediated toxicity: The magnetoliposome model*. Biomaterials, 2009. **30**(22): p. 3691-3701.
191. Ferro, S., et al., *Efficient photoinactivation of methicillin-resistant Staphylococcus aureus by a novel porphyrin incorporated into a poly-cationic liposome*. Int J Biochem Cell Biol, 2007. **39**(5): p. 1026-1034.
192. Zeina, B., et al., *Antimicrobial photodynamic therapy: assessment of genotoxic effects on keratinocytes in vitro*. Br J Dermatol, 2003. **148**(2): p. 229-232.
193. Maisch, T., et al., *Photodynamic Effects of Novel XF Porphyrin Derivatives on Prokaryotic and Eukaryotic Cells*. Antimicrob Agents Chemother 2005 **49**(4): p. 1542–1552.
194. Mayhew, S., et al., *Investigation of Cross-resistance to a Range of Photosensitizers, Hyperthermia and UV Light in Two Radiation-induced Fibrosarcoma Cell Strains Resistant to Photodynamic Therapy In Vitro*. Photochem Photobiol, 2001. **73**(1): p. 39-46.
195. Tavares, A., et al., *Antimicrobial Photodynamic Therapy: Study of Bacterial Recovery Viability and Potential Development of Resistance after Treatment*. Mar Drugs, 2010. **8**(1): p. 91-105.
196. Tan, D.S.W., et al., *Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference*. Eur J Cancer, 2010. **46**(12): p. 2166-2177.
197. Hamblin, M.R., et al., *Optical monitoring and treatment of potentially lethal wound infections in vivo*. J Infect Dis, 2003. **187**(11): p. 1717-25.
198. Gad, F., et al., *Targeted photodynamic therapy of established soft-tissue infections in mice*. Photochem Photobiol Sci, 2004. **3**(5): p. 451-458.
199. Zolfaghari, P.S., et al., *In vivo killing of Staphylococcus aureus using a light-activated antimicrobial agent*. BMC Microbiol, 2009. **9**(27).
200. Donnelly, R.F., et al., *Delivery of Methylene Blue and meso-tetra (N-methyl-4-pyridyl) porphine tetra tosylate from cross-linked poly(vinyl alcohol) hydrogels: A potential means of photodynamic therapy of infected wounds*. J Photochem Photobiol, B Biol, 2009. **96**(3): p. 223-231.

201. Perni, S., et al., *Antibacterial Activity of Light-Activated Silicone Containing Methylene Blue and Gold Nanoparticles of Different Sizes*. J Clust Sci, 2010. **21**(3): p. 427-438.
202. Perni, S., et al., *The antimicrobial properties of light-activated polymers containing methylene blue and gold nanoparticles*. Biomaterials, 2009. **30**(1): p. 89-93.
203. Perni, S., et al., *Toluidine blue-containing polymers exhibit potent bactericidal activity when irradiated with red laser light*. J Mater Chem, 2009. **19**(18): p. 2715-2715.
204. Trautner Bw, D.R.O., *Catheter-associated infections: Pathogenesis affects prevention*. Arch Intern Med, 2004. **164**(8): p. 842-850.
205. Damoiseau, X., et al., *Increase of the photosensitizing efficiency of the Bacteriochlorin a by liposome-incorporation*. J. Photochem. Photobiol., B: Biol, 2001. **60**(1): p. 50-60.
206. Muehlmann, L.A., et al., *Liposomal photosensitizers: potential platforms for anticancer photodynamic therapy*. Braz J Med Biol Res, 2011. **44**(8): p. 729-37.
207. Konan, Y.N., R. Gurny, and E. Allémann, *State of the art in the delivery of photosensitizers for photodynamic therapy*. J. Photochem. Photobiol., B: Biol, 2002. **66**(2): p. 89-106.
208. Allison, R.R., et al., *Bio-nanotechnology and photodynamic therapy—State of the art review*. Photodiagnosis Photodyn Ther, 2008. **5**(1): p. 19-28.
209. Schwiertz, J., et al., *Calcium phosphate nanoparticles as efficient carriers for photodynamic therapy against cells and bacteria*. Biomaterials, 2009. **30**(19): p. 3324-3331.
210. Bombelli, C., et al., *New Cationic Liposomes as Vehicles of m-Tetrahydroxyphenylchlorin in Photodynamic Therapy of Infectious Diseases*. Mol Pharm, 2008. **5**(4): p. 672-679.
211. Koo, Y.-E.L., et al., *Photonic explorers based on multifunctional nanoplatfoms for biosensing and photodynamic therapy*. Appl Opt, 2007. **46**(10): p. 1924-30.
212. Derycke, A.S.L. and P.A.M. de Witte, *Liposomes for photodynamic therapy*. Adv Drug Deliv Rev, 2004. **56**(1): p. 17-30.
213. Fadel, M., et al., *Liposomal methylene blue hydrogel for selective photodynamic therapy of acne vulgaris*. J Drugs Dermatol, 2009. **8**(11): p. 983-90.
214. Séguier, S., et al., *Impact of photodynamic therapy on inflammatory cells during human chronic periodontitis*. J. Photochem. Photobiol., B: Biol, 2010. **101**(3): p. 348-354.
215. Ferro, S., et al., *Inclusion of 5-[4-(1-Dodecanoylpyridinium)]-10,15,20-triphenylporphine in Supramolecular Aggregates of Cationic Amphiphilic Cyclodextrins: Physicochemical Characterization of the Complexes and Strengthening of the Antimicrobial Photosensitizing Activity*. Biomacromolecules, 2009. **10**(9): p. 2592-2600.
216. Ferro, S., et al., *Inactivation of methicillin-resistant Staphylococcus aureus (MRSA) by liposome-delivered photosensitising agents*. J. Photochem. Photobiol., B: Biol, 2006. **83**(2): p. 98-104.
217. Tsai, T., et al., *Improved photodynamic inactivation of gram-positive bacteria using hematoporphyrin encapsulated in liposomes and micelles*. Lasers Surg Med, 2009. **41**(4): p. 316-322.
218. Chatterjee, D.K., L.S. Fong, and Y. Zhang, *Nanoparticles in photodynamic therapy: An emerging paradigm*. Adv Drug Deliv Rev, 2008. **60**(15): p. 1627-1637.
219. Klepac-Ceraj, V., et al., *Photodynamic effects of methylene blue-loaded polymeric nanoparticles on dental plaque bacteria*. Lasers Surg Med, 2011. **43**(7): p. 600-606.
220. Pagonis, T.C., et al., *Nanoparticle-based Endodontic Antimicrobial Photodynamic Therapy*. J Endod, 2010. **36**(2): p. 322-328.

221. Perni, S., et al., *Nanoparticles: their potential use in antibacterial photodynamic therapy*. Photochem Photobiol Sci, 2011. **10**(5): p. 712-720.
222. Gil-Tomas, J., et al., *Lethal photosensitisation of Staphylococcus aureus using a toluidine blue O-tiopronin-gold nanoparticle conjugate*. J Mater Chem, 2007. **17**(35): p. 3739-3746.
223. Yanyan, G., R. Snezna, and Z. Peng, *Rose Bengal-decorated silica nanoparticles as photosensitizers for inactivation of gram-positive bacteria*. Nanotechnology, 2010. **21**(6): p. 065102.
224. Banerjee, I., et al., *Photoactivated Antimicrobial Activity of Carbon Nanotube–Porphyrin Conjugates*. Langmuir, 2010. **26**(22): p. 17369-17374.
225. Mosinger, J., et al., *Bactericidal nanofabrics based on photoproduction of singlet oxygen*. J Mater Chem, 2007. **17**(2): p. 164-166.
226. Mosinger, J.i., et al., *Fluorescent Polyurethane Nanofabrics: A Source of Singlet Oxygen and Oxygen Sensing*. Langmuir, 2010. **26**(12): p. 10050-10056.
227. Arenbergerova, M., et al., *Light-activated nanofibre textiles exert antibacterial effects in the setting of chronic wound healing*. Exp Dermatol, 2012. **21**(8): p. 619-624.
228. Lim, K.S., K.W. Oh, and S.H. Kim, *Antimicrobial activity of organic photosensitizers embedded in electrospun nylon 6 nanofibers*. Polym Int, 2012: p. n/a-n/a.
229. Jin, L., et al., *Electrospun fibers and tissue engineering*. J Biomed Nanotechnol, 2012. **8**(1): p. 1-8.
230. Holzwarth, J.M. and P.X. Ma, *Biomimetic nanofibrous scaffolds for bone tissue engineering*. Biomaterials, 2011. **32**(36): p. 9622-9629.
231. Inoguchi, H., et al., *Mechanical responses of a compliant electrospun poly(l-lactide-co-ε-caprolactone) small-diameter vascular graft*. Biomaterials, 2006. **27**(8): p. 1470-1478.
232. Thomas, V., et al., *Mechano-morphological studies of aligned nanofibrous scaffolds of polycaprolactone fabricated by electrospinning*. J Biomater Sci Polym Ed, 2006. **17**(9): p. 969-984.
233. Mohammadi, Y., et al., *Nanofibrous poly(epsilon-caprolactone)/poly(vinyl alcohol)/chitosan hybrid scaffolds for bone tissue engineering using mesenchymal stem cells*. Int J Artif Organs, 2007. **30**(3): p. 204-211.
234. Schnell, E., et al., *Guidance of glial cell migration and axonal growth on electrospun nanofibers of poly-ε-caprolactone and a collagen/poly-ε-caprolactone blend*. Biomaterials, 2007. **28**(19): p. 3012-3025.
235. Sahoo, S., et al., *Characterization of a novel polymeric scaffold for potential application in tendon/ligament tissue engineering*. Tissue Eng, 2006. **12**(1): p. 91-99.
236. Jayarama Reddy, V., et al., *Nanofibrous structured biomimetic strategies for skin tissue regeneration*. Wound Repair Regen, 2012: p. n/a-n/a.
237. Lee, C.H., et al., *Nanofiber alignment and direction of mechanical strain affect the ECM production of human ACL fibroblast*. Biomaterials, 2005. **26**(11): p. 1261-1270.
238. Matusevičiūtė, A., et al., *Formation of PVA Nanofibres with Iodine by Electrospinning*. Fibers Text East Eur, 2012. **3**(92): p. 21-25.
239. Elakkiya, T., et al., *Biocompatibility studies of electrospun nanofibrous membrane of PLLA-PVA blend*. J Appl Polym Sci, 2012: p. n/a-n/a.
240. Ajao, J., et al., *Electric-magnetic field-induced aligned electrospun poly (ethylene oxide) (PEO) nanofibers*. J Mater Sci, 2010. **45**(9): p. 2324-2329.
241. Sombatmankhong, K., et al., *Electrospun fiber mats of poly(3-hydroxybutyrate), poly(3-hydroxybutyrate-co-3-hydroxyvalerate), and their blends*. J Polym Sci, Part B: Polym Phys, 2006. **44**(19): p. 2923-2933.

242. Tong, H.-W. and M. Wang, *Electrospinning of poly(hydroxybutyrate-co-hydroxyvalerate) fibrous tissue engineering scaffolds in two different electric fields*. Polym Eng Sci, 2011. **51**(7): p. 1325-1338.
243. Kapritchkoff, F.M., et al., *Enzymatic recovery and purification of polyhydroxybutyrate produced by Ralstonia eutropha*. J Biotechnol, 2006. **122**(4): p. 453-462.
244. Chen, L.J. and M. Wang, *Production and evaluation of biodegradable composites based on PHB-PHV copolymer*. Biomaterials, 2002. **23**(13): p. 2631-2639.
245. Reusch, R.N., A.W. Sparrow, and J. Gardiner, *Transport of poly- β -hydroxybutyrate in human plasma*. Biochim Biophys Acta Lipids Lipid Metabol, 1992. **1123**(1): p. 33-40.
246. Foster, L.J.R. and B.J. Tighe, *Enzymatic assay of hydroxybutyric acid monomer formation in poly(β -hydroxybutyrate) degradation studies*. Biomaterials, 1995. **16**(4): p. 341-343.
247. Chan, R.T.H., et al., *Application of Polyethylene Glycol to Promote Cellular Biocompatibility of Polyhydroxybutyrate Films*. Int J Polym Sci, 2011. **2011**.
248. Volova, T., et al., *Results of biomedical investigations of PHB and PHB/PHV fibers*. Biochem Eng J, 2003. **16**(2): p. 125-133.
249. Rodrigues, J.A.F.R., D.F. Parra, and A.B. Lugão, *Crystallization on films of PHB/PEG blends*. J Therm Anal Calorim, 2005. **79**(2): p. 379-381.
250. Lee, S.S., et al., *Bone regeneration with low dose BMP-2 amplified by biomimetic supramolecular nanofibers within collagen scaffolds*. Biomaterials, 2013. **34**(2): p. 452-459.
251. Martins, A., et al., *Osteogenic induction of hBMSCs by electrospun scaffolds with dexamethasone release functionality*. Biomaterials, 2010. **31**(22): p. 5875-5885.
252. Bassi, A., et al., *A Novel Synthetic Bone Graft Substitute for Osteoporotic Patients*, in *The 2nd International Symposium on Surface and Interface of Biomaterials (ISSIB-II)*. 2011: Hong Kong.
253. Fathi-Azarbayjani, A., et al., *Novel Vitamin and Gold-Loaded Nanofiber Facial Mask for Topical Delivery*. AAPS PharmSciTech, 2010. **11**(3): p. 1164-1170.
254. Plessis, D.M.d., *Fabrication and characterization of anti-microbial and biofouling resistant nanofibers with silver nanoparticles and immobilized enzymes for application in water filtration*. 2011, University of Stellenbosch: Stellenbosch.
255. Huang, L.Y., et al., *Electrospinning of amphipathic chitosan nanofibers for surgical implants application*. J Nanosci Nanotechnol., 2012. **12**(6): p. 5066-5070.
256. Chen, X.N., et al., *Multifunctional surfaces with biomimetic nanofibres and drug-eluting micro-patterns for infection control and bone tissue formation*. Eur Cell Mater, 2012. **24**(24): p. 237-248.
257. Said, S.S., et al., *Bioburden-responsive antimicrobial PLGA ultrafine fibers for wound healing*. Eur J Pharm Biopharm, 2012. **80**(1): p. 85-94.
258. Yu, D.G., et al., *Polyacrylonitrile nanofibers coated with silver nanoparticles using a modified coaxial electrospinning process*. Int J Nanomedicine, 2012. **7**: p. 5725-5732.
259. del Valle, et al., *Biodegradable polyesters reinforced with triclosan loaded polylactide micro/nanofibers: Properties, release and biocompatibility*. EXPRESS Polymer Letters, 2012. **6**(266-282).
260. Mal'kovskaya, Y.P., et al., *Production of antimicrobial nanofibers by electroforming*. Fibre Chem, 2012. **43**(6): p. 412-416.
261. Liu, X., et al., *Antimicrobial electrospun nanofibers of cellulose acetate and polyester urethane composite for wound dressing*. J Biomed Mater Res B Appl Biomater, 2012. **100B**(6): p. 1556-1565.

262. Jin, Y. and X. Zhao, *cytotoxicity of photoactive nanoparticles*, in *Safety of Nanoparticles, From Manufacturing to Medical Applications*, W. TJ, Editor. 2009, Springer: New York.
263. *The Effective Use of Hydrofera Blue® Bacteriostatic Dressing in Difficult-to-Heal Wounds: An Evaluation of Six Case Studies*, <http://woundcare.org/wp-content/uploads/2012/08/Hydrofera-Blue-Clinical-Monograph-Brochure.pdf>.
264. Wainwright, M., 'Safe' photoantimicrobials for skin and soft-tissue infections. *Int J Antimicrob Agents*, 2010. **36**(1): p. 14-18.
265. Junqueira, H.C., et al., *Modulation of methylene blue photochemical properties based on adsorption at aqueous micelle interfaces*. *Phys Chem Chem Phys*, 2002. **4**(11): p. 2320-2328.
266. Tardivo, J.P., et al., *New photodynamic therapy protocol to treat AIDS-related Kaposi's sarcoma*. *Photomed Laser Surg.*, 2006. **24**(4): p. 528-31.
267. Peloi, L., et al., *Photodynamic effect of light-emitting diode light on cell growth inhibition induced by methylene blue*. *J Bioscience*, 2008. **33**(2): p. 231-237.
268. Heydrick, S.J., et al., *Intraperitoneal Administration of Methylene Blue Attenuates Oxidative Stress, Increases Peritoneal Fibrinolysis, and Inhibits Intraabdominal Adhesion Formation*. *J Surg Res*, 2007. **143**(2): p. 311-319.
269. Salaris, S.C., C.F. Babbs, and W.D. Voorhees Iii, *Methylene blue as an inhibitor of superoxide generation by xanthine oxidase: A potential new drug for the attenuation of ischemia/reperfusion injury*. *Biochem Pharmacol*, 1991. **42**(3): p. 499-506.
270. Kluger, Y., et al., *Reduction in formation of peritoneal adhesions by methylene blue in rats: a dose response study*. *Eur J Surg*, 2000. **166**(7): p. 568-71.
271. Galili, Y., et al., *Reduction of Surgery-induced Peritoneal Adhesions by Methylene Blue*. *Am J Surg*, 1998. **175**(1): p. 30-32.
272. Vandepitte, J., et al., *Basic laboratory procedures in clinical bacteriology*. Geneva: World Health Organization, 1991: p. 13-15.
273. Howard, D.H., *The preservation of bacteria by freezing in glycerol broth*. *J Bacteriol*, 1956. **71**(5): p. 625.
274. Romanova, N.A., et al., *Assessment of Photodynamic Destruction of Escherichia coli O157:H7 and Listeria monocytogenes by Using ATP Bioluminescence*. *Appl Environ Microbiol.*, 2003. **69**(11)(11): p. 6393-6398.
275. Andrews, J.M., *BSAC standardized disc susceptibility testing method (version 8)*. *J Antimicrob Chemother*, 2009. **64**(3): p. 454-489.
276. Usacheva, M.N., et al., *Interaction of the photobactericides methylene blue and toluidine blue with a fluorophore in Pseudomonas aeruginosa cells*. *Lasers Surg Med*, 2008. **40**(1): p. 55-61.
277. Gu, S.-Y., et al., *Electrospinning of gelatin and gelatin/poly(l-lactide) blend and its characteristics for wound dressing*. *Mater Sci Eng C*, 2009. **29**(6): p. 1822-1828.
278. Fong, H., I. Chun, and D.H. Reneker, *Beaded nanofibers formed during electrospinning*. *Polymer*, 1999. **40**(16): p. 4585-4592.
279. Okhawilai, M., et al., *Preparation of Thai silk fibroin/gelatin electrospun fiber mats for controlled release applications*. *Int J Biol Macromol*, 2010. **46**(5): p. 544-550.
280. Shastri, V.P., J.C. Sy, and I.-W. Chen, *Emulsion-based control of electrospun fiber morphology*, U.S.P.A. Publication, Editor. 2007: USA.
281. Liao, Y., et al., *Preparation, characterization, and encapsulation/release studies of a composite nanofiber mat electrospun from an emulsion containing poly(lactic-co-glycolic acid)*. *Polymer*, 2008. **49**(24): p. 5294-5299.
282. Khan, B.A., et al., *Basics of pharmaceutical emulsions: A review*. *AJPP*, 2011. **5** (25): p. 2715-2725.

283. Mishra, M., et al., *Basics and Potential Applications of Surfactants – A Review*. International Journal of PharmTech Research, 2009. **1**(4): p. 1354-1365.
284. Pignatello, R. and F. Castelli, *Calorimetric techniques to study the interaction of drugs with biomembrane models*. J Pharm Bioallied Sci, 2011. **3**(1): p. 1-2.
285. Medvecky, L., *Microstructure and Properties of Polyhydroxybutyrate-Chitosan-Nanohydroxyapatite Composite Scaffolds*. The Scientific World Journal, 2012. **2012**: p. 8.
286. Zong, X., et al., *Structure and process relationship of electrospun bioabsorbable nanofiber membranes*. Polymer, 2002. **43**(16): p. 4403-4412.
287. Gu, S.Y., J. Ren, and Q.L. Wu, *Preparation and structures of electrospun PAN nanofibers as a precursor of carbon nanofibers*. Synth Met, 2005. **155**(1): p. 157-161.
288. Hayati, I., A.I. Bailey, and T.F. Tadros, *Investigations into the mechanisms of electrohydrodynamic spraying of liquids: I. Effect of electric field and the environment on pendant drops and factors affecting the formation of stable jets and atomization*. J Colloid Interface Sci, 1987. **117**(1): p. 205-221.
289. Fang, X., et al., *Fabrication and characterization of water-stable electrospun polyethyleneimine/polyvinyl alcohol nanofibers with super dye sorption capability*. New J Chem, 2011. **35**(2): p. 360-368.
290. Wei, Z., et al., *The preparation and adsorption properties of electrospun aramid nanofibers*. J Polym Sci, Part B: Polym Phys, 2012. **50**(20): p. 1414-1420.
291. Rawal, A., *Structural analysis of pore size distribution of nonwovens †*. J Text I, 2010. **101**(4): p. 350-359.
292. Zhu, Q. and Y. Li, *Effects of pore size distribution and fiber diameter on the coupled heat and liquid moisture transfer in porous textiles*. Int J Heat Mass Transf, 2003. **46**(26): p. 5099-5111.
293. Sezer, A., et al., *Chitosan film containing fucoidan as a wound dressing for dermal burn healing: Preparation and in vitro/in vivo evaluation*. AAPS PharmSciTech, 2007. **8**(2): p. E94-E101.
294. Cui, W., et al., *Investigation of Drug Release and Matrix Degradation of Electrospun Poly(dl-lactide) Fibers with Paracetamol Inoculation*. Biomacromolecules, 2006. **7**(5): p. 1623-1629.
295. Tuite, E.M. and J.M. Kelly, *New trends in photobiology: Photochemical interactions of methylene blue and analogues with DNA and other biological substrates*. J Photochem Photobiol, B Biol, 1993. **21**(2-3): p. 103-124.
296. Usacheva, M.N., M.C. Teichert, and M.A. Biel, *Comparison of the methylene blue and toluidine blue photobactericidal efficacy against gram-positive and gram-negative microorganisms*. Lasers Surg Med, 2001. **29**(2): p. 165-173.
297. Tang, C.-L., et al., *A Randomized Controlled Trial of 0.5% Ferric Hyaluronate Gel (Intergel) in the Prevention of Adhesions Following Abdominal Surgery*. Ann Surg, 2006. **243**(4): p. 449-455 10.1097/01.sla.0000207837.71831.a2.
298. Ray, N.F., et al., *Abdominal Adhesiolysis: Inpatient Care and Expenditures in the United States in 1994*. J Am Coll Surg, 1998. **186**(1): p. 1-9.
299. Schnüriger, B., et al., *Prevention of postoperative peritoneal adhesions: a review of the literature*. Am J Surg, 2011. **201**(1): p. 111-121.
300. Duron, J.J., *Postoperative intraperitoneal adhesion pathophysiology*. Colorectal Dis, 2007. **9**: p. 14-24.
301. Holmdahl, L., *The role of fibrinolysis in adhesion formation*. Eur J Surg Suppl., 1997. **577**: p. 24-31.
302. Norrman, B., P. WallÉN, and M. RÅNby, *Fibrinolysis mediated by tissue plasminogen activator*. Eur J Biochem, 1985. **149**(1): p. 193-200.

303. Andreasen, P.A., et al., *Plasminogen activator inhibitors: hormonally regulated serpins*. Mol Cell Endocrinol, 1990. **68**(1): p. 1-19.
304. Cheong, Y.C., et al., *Peritoneal healing and adhesion formation/reformation*. Hum Reprod Update, 2001. **7**(6): p. 556-566.
305. Munireddy, S., S.L. Kavalukas, and A. Barbul, *Intra-abdominal Healing: Gastrointestinal Tract and Adhesions*. Surg Clin North Am, 2010. **90**(6): p. 1227-1236.
306. Rout, U.K. and M.P. Diamond, *Role of plasminogen activators during healing after uterine serosal lesioning in the rat*. Fertil Steril, 2003. **79**(1): p. 138-145.
307. Ellis, H., et al., *Adhesion-related hospital readmissions after abdominal and pelvic surgery: a retrospective cohort study*. The Lancet, 1999. **353**(9163): p. 1476-1480.
308. Maciver, A.H., M. McCall, and A.M. James Shapiro, *Intra-abdominal adhesions: Cellular mechanisms and strategies for prevention*. Int J Surg, 2011. **9**(8): p. 589-594.
309. Kamel, R.M., *Prevention of postoperative peritoneal adhesions*. Eur J Obstet Gynecol Reprod Biol, 2010. **150**(2): p. 111-118.
310. Arikan, S., et al., *An evaluation of low molecular weight heparin and hyperbaric oxygen treatment in the prevention of intra-abdominal adhesions and wound healing*. Am J Surg, 2005. **189**(2): p. 155-160.
311. Rodgers, K.E., et al., *Reduction of adhesion formation by intraperitoneal administration of arg-gly-asp-containing peptides*. Fertil Steril, 1998. **70**(6): p. 1131-1138.
312. Montz, F.J., et al., *Ketorolac Tromethamine, a Nonsteroidal Anti-inflammatory Drug: Ability to Inhibit Post-radical Pelvic Surgery Adhesions in a Porcine Model*. Gynecol Oncol, 1993. **48**(1): p. 76-79.
313. Cashman, J., et al., *Camptothecin-loaded films for the prevention of postsurgical adhesions*. Inflammation Research, 2004. **53**(8): p. 355-362.
314. de la Portilla, F., et al., *Prevention of Peritoneal Adhesions by Intraperitoneal Administration of Vitamin E: An Experimental Study in Rats*. Dis Colon Rectum, 2004. **47**(12): p. 2157-2161 10.1007/s10350-004-0741-6.
315. Dinc, S., et al., *Methylene blue prevents surgery-induced peritoneal adhesions but impairs the early phase of anastomotic wound healing*. Can J Surg., 2006 **49**(5): p. 321-8.
316. Risberg, B., *Adhesions: preventive strategies*. Eur J Surg Suppl., 1997. **577**: p. 32-39.
317. Becker, J.M., et al., *Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study*. J Am Coll Surg., 1996. **183**(4): p. 297-306.
318. Raftery, A.T., *Absorbable haemostatic materials and intraperitoneal adhesion formation*. Br J Surg, 1980. **67**(1): p. 57-58.
319. Reid, R.L., et al., *A randomized clinical trial of oxidized regenerated cellulose adhesion barrier (Interceed, TC7) alone or in combination with heparin*. Fertil Steril, 1997. **67**(1): p. 23-29.
320. Mamoudieh, M., N. Mirkheshti, and S.A. Alavi, *Evaluation of agar films in the prevention of postoperative peritoneal adhesions in an animal model*. Ulus Travma Acil Cerrahi Derg, 2011. **17**(2): p. 108-112.
321. Paulo, N.M., et al., *Use of chitosan membrane associated with polypropylene mesh to prevent peritoneal adhesion in rats*. J Biomed Mater Res B Appl Biomater, 2009. **91B**(1): p. 221-227.
322. Sahin, Y. and A. Saglam, *Synergistic effects of carboxymethylcellulose and low molecular weight heparin in reducing adhesion formation in the rat uterine horn model*. Acta Obstet Gynecol Scand, 1994. **73**(1): p. 70-73.

323. Gong, C., et al., *Improving intraperitoneal chemotherapeutic effect and preventing postsurgical adhesions simultaneously with biodegradable micelles*. *Nanomed Nanotechnol*, 2012. **8**(6): p. 963-973.
324. Yagmurlu, A., et al., *Reduction of Surgery-Induced Peritoneal Adhesions by Continuous Release of Streptokinase from a Drug Delivery System*. *Eur Surg Res*, 2003. **35**(1): p. 46-49.
325. Oncel, M., et al., *The Effectiveness of Systemic Antibiotics in Preventing Postoperative, Intraabdominal Adhesions in an Animal Model*. *J Surg Res*, 2001. **101**(1): p. 52-55.
326. Haney, A.F., et al., *Expanded polytetrafluoroethylene (Gore-Tex Surgical Membrane) is superior to oxidized regenerated cellulose (Interceed TC7+) in preventing adhesions*. *Fertil Steril.*, 1995. **63**(5): p. 1021-6.
327. Zuhlke, H.V., E.M. Lorenz, and E.M. Straub, *Pathophysiology and classification of adhesions*. *Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir.* , 1990. **345**: p. 1009–1016.
328. Duran, B., et al., *Reduction of Postoperative Adhesions by N,O-Carboxymethylchitosan and Spermine NONOate in Rats*. *Experimental Animals*, 2003. **52**(4): p. 267-272.
329. Dinc, S., et al., *Methylene blue prevents surgery-induced peritoneal adhesions but impairs the early phase of anastomotic wound healing*. *Can J Surg.*, 2006. **49** (5): p. 321–328.
330. Mayer, B., F. Brunner, and K. Schmidt, *Inhibition of nitric oxide synthesis by methylene blue*. *Biochem Pharmacol*, 1993. **45**(2): p. 367-374.
331. Panahi, F., et al., *Macroscopic and pathological assessment of methylene blue and normal saline on postoperative adhesion formation in a rat cecum model*. *Int J Surg*, 2012. **10**(9): p. 537-541.
332. Matsuda, S., et al., *Evaluation of the antiadhesion potential of UV cross-linked gelatin films in a rat abdominal model*. *Biomaterials*, 2002. **23**(14): p. 2901-2908.
333. Falabella, C.A. and W. Chen, *Cross-Linked Hyaluronic Acid Films to Reduce Intra-Abdominal Postsurgical Adhesions in an Experimental Model*. *Dig Surg* 2009. **26**(6).
334. Duran, H.E., et al., *Lipiodol™ versus methylene blue for prevention of postsurgical adhesion formation in a rat model*. *Eur J Obstet Gynecol Reprod Biol*, 2002. **102**(1): p. 80-82.
335. Spasova, M., et al., *Preparation of PLLA/PEG Nanofibers by Electrospinning and Potential Applications*. *J Bioact Compat Polym*, 2007. **22**(1): p. 62-76.
336. Lowery, J.L., N. Datta, and G.C. Rutledge, *Effect of fiber diameter, pore size and seeding method on growth of human dermal fibroblasts in electrospun poly(ϵ -caprolactone) fibrous mats*. *Biomaterials*, 2010. **31**(3): p. 491-504.
337. Lee, J.H., et al., *The Effect of Fluid Shear Stress on Endothelial Cell Adhesiveness to Polymer Surfaces with Wettability Gradient*. *J Colloid Interface Sci*, 2000. **230**(1): p. 84-90.
338. Cheong, Y.C., et al., *The correlation of adhesions and peritoneal fluid cytokine concentrations: a pilot study*. *Hum Reprod*, 2002. **17**(4): p. 1039-1045.
339. ten Raa, S., et al., *The Role of Neutrophils and Oxygen Free Radicals in Post-Operative Adhesions*. *J Surg Res*, 2006. **136**(1): p. 45-52.
340. Reed, K.L., et al., *A neurokinin-1 receptor antagonist that reduces intra-abdominal adhesion formation decreases oxidative stress in the peritoneum*. *Am J Physiol Gastrointest Liver Physiol*, 2007. **293**(3): p. G544-G551.
341. Vural, B., et al., *The role of neutrophils in the formation of peritoneal adhesions*. *Hum Reprod*, 1999. **14**(1): p. 49-54.

342. Liu, X., et al., *Electrospun Nanofibre Membranes as Wound Dressing Materials*. Advances in Science and Technology, 2008. **57**: p. 125-130.
343. Matusevičiūtė A, et al., *Formation of PVA Nanofibres with Iodine by Electrospinning*. Fibers & Textiles in Eastern Europe, 2012. **3**(92): p. 21-25.
344. Hu, W., Z.M. Huang, and X.Y. Liu, *Development of braided drug-loaded nanofiber sutures*. Nanotechnology, 2010. **21**(31): p. 315104.
345. Wallence W and Leung, *Nanofiber filter facemasks and cabin filters*. , U.S. Application, Editor. 2008.
346. Fathi-Azarbayjani, A., et al., *Novel vitamin and gold-loaded nanofiber facial mask for topical delivery*. AAPS PharmSciTech, 2010. **11**(3): p. 1164-70.
347. Balha CM, To H, and P. LX, *Coatings for promoting endothelization of medical devices*. , U.S. Application, Editor. 2008.
348. Wang C, et al., *Conventional Electrospinning vs. Emulsion Electrospinning: A Comparative Study on the Development of Nanofibrous Drug/Biomolecule Delivery Vehicles*. Adv Mat Res, 2012. **410**: p. 118-121.
349. Kim, K., et al., *Incorporation and controlled release of a hydrophilic antibiotic using poly(lactide-co-glycolide)-based electrospun nanofibrous scaffolds*. Journal of Controlled Release 2004. **98**(1): p. 47-56.
350. Amna T, et al., *Antibacterial activity and interaction mechanism of electrospun zinc-doped titania nanofibers*. Appl Microbiol Biotechnol, 2012. **93**(2): p. 743-751.
351. Ren, X., et al., *Biocidal nanofibers via electrospinning*. J Appl Polym Sci, 2012: p. n/a-n/a.
352. Kenawy el, R., S.D. Worley, and R. Broughton, *The chemistry and applications of antimicrobial polymers: a state-of-the-art review*. Biomacromolecules, 2007. **8**(5): p. 1359-84.
353. Qun, X.L., et al., *Antibacterial Nanofibers of Self-quaternized Block Copolymers of 4-Vinyl Pyridine and Pentachlorophenyl Acrylate*. High Perform Polym, 2009.
354. Huang, C., et al., *Stimuli-responsive electrospun fibers and their applications*. Chem Soc Rev, 2011. **40**(5): p. 2417-2434.
355. Andersen, R., et al., *Treatment of periodontal disease by photodisinfection compared to scaling and root planing*. J Clin Dent, 2007. **18**(2): p. 34-38.
356. Garcez, A.S., et al., *Antimicrobial photodynamic therapy combined with conventional endodontic treatment to eliminate root canal biofilm infection*. Lasers Surg Med, 2007. **39**(1): p. 59-66.
357. Raghavendra, M., A. Koregol, and S. Bhola, *Photodynamic therapy: a targeted therapy in periodontics*. Aust Dent J, 2009. **54**: p. S102-S109.
358. Mima, E.G.d.O., et al., *Susceptibility of Candida albicans to photodynamic therapy in a murine model of oral candidosis*. Oral Surg Oral Med Oral Pathol Oral Radiol Endod., 2010. **109**(3): p. 392-401.
359. Youssef, T., et al., *Evaluation of hypericin-loaded solid lipid nanoparticles: Physicochemical properties, photostability and phototoxicity*. Pharm Dev Technol, 2012. **17**(2): p. 177-186.
360. Fushimi, T., et al., *Green light emitting diodes accelerate wound healing: Characterization of the effect and its molecular basis in vitro and in vivo*. Wound Repair Regen, 2012. **20**(2): p. 226-235.
361. Vinck, E., et al., *Increased fibroblast proliferation induced by light emitting diode and low power laser irradiation*. Lasers Med Sci, 2003. **18**(2): p. 95 - 99.
362. Wang, I., *Photodynamic therapy and laser-based diagnostic studies of malignant tumours*, in *The Jubileum Institute, Department of Oncology*. 1999, Lund University: Lund, Sweden.

363. Fischer, F., et al., *A chemical dosimeter for the determination of the photodynamic activity of photosensitizers*. Clin Chim Acta, 1998. **274**(1): p. 89-104.
364. Rabello, B.R., et al., *Singlet oxygen dosimetry using uric acid as a chemical probe: Systematic evaluation*. J Photochem Photobiol A Chem, 2012. **238**(0): p. 53-62.
365. Gerola, A.P., et al., *Chemical determination of singlet oxygen from photosensitizers illuminated with LED: New calculation methodology considering the influence of photobleaching*. J Photochem Photobiol A Chem, 2012. **232**(0): p. 14-21.
366. Lang, K., J. Mosinger, and D.M. Wagnerová, *Photophysical properties of porphyrinoid sensitizers non-covalently bound to host molecules; models for photodynamic therapy*. Coord Chem Rev, 2004. **248**(3-4): p. 321-350.
367. Chang, C.-C., et al., *Enhancement of light scattering and photoluminescence in electrospun polymer nanofibers*. Opt Express, 2010. **18**(S2): p. A174-A184.
368. Pagliara, S., et al., *Electrospun light-emitting nanofibers as excitation source in microfluidic devices*. Lab Chip, 2009. **9**(19): p. 2851-2856.
369. Rehammar, R., et al., *Diffraction from carbon nanofiber arrays*. Opt Lett, 2012. **37**(1): p. 100-102.
370. McCarthy, J.R., et al., *Polymeric Nanoparticle Preparation that Eradicates Tumors*. Nano Lett, 2005. **5**(12): p. 2552-2556.
371. Neri, C.R., et al., *Determination of the photodynamic activity of porphyrins: Potential photosensitizers for treatment of age-related macular degeneration*. Mater Sci, 2002. **20**(2): p. 97-103.
372. Becker, B.F., *Towards the physiological function of uric acid*. Free Radic Biol Med, 1993. **14**(6): p. 615-631.
373. Jesenská, S., et al., *Antibacterial nanofiber materials activated by light*. J Biomed Mater Res A, 2011. **99A**(4): p. 676-683.
374. Huang, L., T. Dai, and M.R. Hamblin, *Antimicrobial Photodynamic Inactivation and Photodynamic Therapy for Infections*. Methods Mol Biol. , 2010. **635**: p. 155-73.
375. Maisch, T., et al., *The role of singlet oxygen and oxygen concentration in photodynamic inactivation of bacteria*. Proc Natl Acad Sci 2007. **104**(17): p. 7223-7228.
376. Castano, A.P., T.N. Demidova, and M.R. Hamblin, *Mechanisms in photodynamic therapy: part one—photosensitizers, photochemistry and cellular localization*. Photodiagnosis Photodyn Ther, 2004. **1**(4): p. 279-293.
377. Heggors, J.P., *Assessing and controlling wound infection*. Clin Plast Surg. , 2003 **30**(1): p. 25-35.
378. Alemdaroğlu, C., et al., *An investigation on burn wound healing in rats with chitosan gel formulation containing epidermal growth factor*. Burns, 2006. **32**(3): p. 319-327.
379. Ribu, L., et al., *A longitudinal study of patients with diabetes and foot ulcers and their health-related quality of life: wound healing and quality-of-life changes*. J Diabetes Complications, 2008. **22**(6): p. 400-407.
380. Moffatt, C.J., et al., *Psychological factors in leg ulceration: a case-control study*. Br J Dermatol, 2009. **161**(4): p. 750-756.
381. Sen, C.K., et al., *Human skin wounds: A major and snowballing threat to public health and the economy*. Wound Repair Regen, 2009. **17**(6): p. 763-771.
382. White, B., *National best practice and evidence based guidelines for wound management.*, D.S. Hospital, Editor. 2010, Health Service Executive: Dublin, Ireland.
383. Lipsky, B.A. and C. Hoey, *Topical Antimicrobial Therapy for Treating Chronic Wounds*. Clin Infect Dis, 2009. **49**(10): p. 1541-1549.
384. Murphy, P.S. and G.R.D. Evans., *Advances in Wound Healing: A Review of Current Wound Healing Products*. Plast Surg Int, 2012. **2012**.

385. Wolcott, R., K.F. Cutting, and S.E. Dowd, *Surgical site infections: biofilms, dehiscence and delayed healing*. Wounds UK, 2008. **4**(4): p. 108-113.
386. Roche, E.D., et al., *Increasing the presence of biofilm and healing delay in a porcine model of MRSA-infected wounds*. Wound Repair Regen, 2012. **20**(4): p. 537-543.
387. Boucher, H.W. and G.R. Corey, *Epidemiology of Methicillin-Resistant Staphylococcus aureus*. Clin Infect Dis, 2008. **46**(Supplement 5): p. S344-S349.
388. Casey, M.L. and E.R. Chasens, *Community-Associated Methicillin-Resistant Staphylococcus Aureus: Implications for Emergency Department Nursing*. J Emerg Nurs, 2009. **35**(3): p. 224-229.
389. Stephen-Haynes, J., A. Bielby, and R. Searle, *Putting patients first: reducing the human and economic costs of wounds*. Wounds UK, 2011. **7**(3): p. 47-55.
390. Wainwright, M., *Photodynamic medicine and infection control*. J Antimicrob Chemother, 2012. **67**(4): p. 787-788.
391. Maisch, T., et al., *Photodynamic inactivation of multi-resistant bacteria (PIB) – a new approach to treat superficial infections in the 21st century*. J Dtsch Dermatol Ges, 2011. **9**(5): p. 360-366.
392. Tubby, S., M. Wilson, and S. Nair, *Inactivation of staphylococcal virulence factors using a light-activated antimicrobial agent*. BMC Microbiol, 2009. **9**(1): p. 211.
393. Awuah, S.G. and Y. You, *Boron dipyrromethene (BODIPY)-based photosensitizers for photodynamic therapy*. RSC Adv, 2012. **2**(30): p. 11169-11183.
394. Premasiri, A., G. Happawana, and A. Rosen, *Development of high yielding photonic light delivery system for photodynamic therapy of esophageal carcinomas*. 2007: p. 642713-642713.
395. Cassidy, C.M., et al., *Drug delivery strategies for photodynamic antimicrobial chemotherapy: From benchtop to clinical practice*. J Photochem Photobiol, B Biol, 2009. **95**(2): p. 71-80.
396. Longo, J.P.F., L.A. Muehlmann, and R.B.d. Azevedo, *Nanostructured Carriers for Photodynamic Therapy Applications in microbiology*, in *Science against microbial pathogens: communicating current research and technological advances*, A. Méndez-Vilas, Editor. 2011. p. 189-196.
397. Okuda, T., K. Tominaga, and S. Kidoaki, *Time-programmed dual release formulation by multilayered drug-loaded nanofiber meshes*. J Control Release, 2010. **143**(2): p. 258-264.
398. Sell, S., et al., *Extracellular matrix regenerated: tissue engineering via electrospun biomimetic nanofibers*. Polymer International, 2007. **56**(11): p. 1349-1360.
399. Savino, A. and G. Angeli, *Photodynamic inactivation of E. coli by immobilized or coated dyes on insoluble supports*. Water Res, 1985. **19**(12): p. 1465-1469.
400. Ismail, S., et al., *Efficacy of a novel light-activated antimicrobial coating for disinfecting hospital surfaces*. Infect Control Hosp Epidemiol, 2011. **32**(11): p. 1130-1132.
401. Noimark, S., C.W. Dunnill, and I.P. Parkin, *Shining light on materials — A self-sterilising revolution*. Adv Drug Deliv Rev, (0).
402. Tardivo, J.P., et al., *Methylene blue in photodynamic therapy: From basic mechanisms to clinical applications*. Photodiagnosis Photodyn Ther, 2005. **2**(3): p. 175-191.
403. Hashimoto, M.C.E., et al., *Antimicrobial Photodynamic Therapy on Drug-resistant Pseudomonas aeruginosa-induced Infection. An In Vivo Study†*. Photochem Photobiol, 2012. **88**(3): p. 590-595.
404. ElGowelli, H.M., *Re-evaluation of some complementary alternative medicines in the healing of experimentally induced wounds*. 2006.

405. Khan, T.A., *preliminary investigation of chitosan film as dressing for punch biopsy wounds in rats*. J Pharm Pharmaceut Sci 2003. **6**(1): p. 20-26.
406. Fishel, R., et al., *Cyclosporine A impairs wound healing in rats*. J Surg Res, 1983. **34**(6): p. 527-575.
407. Chiquetti Júnior, A., M.A.d.F. Rodrigues, and V.D.A. Delfino, *An experimental model for the study of drug effects on cutaneous healing*. Acta Cir Bras, 2007. **22**: p. 317-321.
408. El-Mas, M.M., et al., *Pioglitazone abrogates cyclosporine-evoked hypertension via rectifying abnormalities in vascular endothelial function*. Biochemical Pharmacology, 2011. **81**(4): p. 526-533.
409. Nakada, C., et al., *Overexpression of miR-210, a downstream target of HIF1 α , causes centrosome amplification in renal carcinoma cells*. J Pathol, 2011. **224**(2): p. 280-288.
410. Li, P., et al., *Ski, a modulator of wound healing and scar formation in the rat skin and rabbit ear*. J Pathol, 2011. **223**(5): p. 659-671.
411. Yao, J.S., et al., *Comparison of doxycycline and minocycline in the inhibition of VEGF-induced smooth muscle cell migration*. Neurochem Int, 2007. **50**(3): p. 524-530.
412. Recker, F., et al., *Cyclosporine A impairs wound healing of ureterocystoneostomy in rats. Scanning electron microscopic examination*. Urol Res, 1989. **17**(1): p. 21-26.
413. Li, J., J. Chen, and R. Kirsner, *Pathophysiology of acute wound healing*. Clin Dermatol, 2007. **25**(1): p. 9-18.
414. Barrientos, S., et al., *PERSPECTIVE ARTICLE: Growth factors and cytokines in wound healing*. Wound Repair Regen, 2008. **16**(5): p. 585-601.
415. Rasik, A.M. and A. Shukla, *Antioxidant status in delayed healing type of wounds*. Int J Exp Pathol, 2000. **81**(4): p. 257-263.
416. Petri, J.B., et al., *Cyclosporine A delays wound healing and apoptosis and suppresses activin beta-A expression in rats*. Eur J Dermatol, 1998 **8**(2): p. 104-13.
417. Lindner, H.B., et al., *Anti-Bacterial Effects of Poly-N-Acetyl-Glucosamine Nanofibers in Cutaneous Wound Healing: Requirement for Akt1*. PLoS One, 2011. **6**(4): p. e18996.
418. Newman, G.R., et al., *Visualisation of bacterial sequestration and bactericidal activity within hydrating Hydrofiber® wound dressings*. Biomaterials, 2006. **27**(7): p. 1129-1139.
419. Walker, M., et al., *Scanning electron microscopic examination of bacterial immobilisation in a carboxymethyl cellulose (AQUACEL®) and alginate dressings*. Biomaterials, 2003. **24**(5): p. 883-890.
420. McCallon, S.K. and J. Hurlow, *Clinical applications for the use of enzymatic debriding ointment and broad-spectrum bacteriostatic foam dressing*. J Wound Ostomy Continence Nurs, 2009 **36**(6): p. 17-24.
421. Adamskaya, N., et al., *Light therapy by blue LED improves wound healing in an excision model in rats*. Injury, 2011. **42**(9): p. 917-921.
422. Erdle, B.J., et al., *Effects of Continuous-Wave (670-nm) Red Light on Wound Healing*. Dermatologic Surgery, 2008. **34**(3): p. 320-325.
423. AlGhamdi, K., A. Kumar, and N. Moussa, *Low-level laser therapy: a useful technique for enhancing the proliferation of various cultured cells*. Lasers Med Sci, 2012. **27**(1): p. 237-249.
424. Demidova-Rice, T.N., et al., *Low-level light stimulates excisional wound healing in mice*. Lasers Med Sci, 2007. **39**(9): p. 706-715.

425. Karu, T.I., L.V. Pyatibrat, and G.S. Kalendo, *Photobiological modulation of cell attachment via cytochrome c oxidase*. Photochem Photobiol Sci, 2004. **3**(2): p. 211-216.
426. Karu, T.I., *Multiple roles of cytochrome c oxidase in mammalian cells under action of red and IR-A radiation*. IUBMB Life, 2010. **62**(8): p. 607-610.
427. Lane, N., *Cell biology: Power games*. Nature, 2006. **443**(7114): p. 901-903.
428. Zhang, Y., et al., *cDNA Microarray Analysis of Gene Expression Profiles in Human Fibroblast Cells Irradiated with Red Light*. J Investig Dermatol, 2003. **120**(5): p. 849-857.
429. Gao, X. and D. Xing, *Molecular mechanisms of cell proliferation induced by low power laser irradiation*. J Biomed Sci, 2009. **16**(1): p. 4.
430. Reddy, G., *Photobiological basis and clinical role of lowintensity lasers in biology and medicine*. J Clin Laser Med Surg, 2004. **22**: p. 141 - 150.
431. Whinfield, A.L. and I. Aitkenhead, *The light revival: does phototherapy promote wound healing? A review*. The Foot, 2009. **19**(2): p. 117-124.
432. Silva, J.C.E., et al., *Evaluation of the use of low level laser and photosensitizer drugs in healing*. Lasers Surg Med, 2004. **34**(5): p. 451-457.
433. Sperandio, F.F., et al., *Photodynamic therapy mediated by methylene blue dye in wound healing*. Photomed Laser Surg. , 2010 **28**(5): p. 581-7.
434. Elsner, J.J., I. Berdicevsky, and M. Zilberman, *In vitro microbial inhibition and cellular response to novel biodegradable composite wound dressings with controlled release of antibiotics*. Acta Biomater, 2011. **7**(1): p. 325-336.
435. Hantash, B.M., et al., *Adult and fetal wound healing*. Front Biosci, 2008. **13**: p. 51-61.
436. Futagami, A., et al., *Wound healing involves induction of cyclooxygenase-2 expression in rat skin*. ab Invest, 2002. **82**(11): p. 1503-1513.
437. Abd-El-Aleem, S.A., et al., *Expression of cyclooxygenase isoforms in normal human skin and chronic venous ulcers*. J Pathol, 2001. **195**(5): p. 616-623.

الملخص العربي

لقد مهدت أنظمة توصيل الدواء البلمرية الطريق لمعظم التطبيقات الطبية الحيوية الواعدة والتكنولوجيا الحيوية. ومن بين تلك التطبيقات، الأنظمة الموضعية التي تلعب دورا هاما فيما يتعلق بالتوصيل الموضعي للدواء في العديد من الأمراض الجلدية، والعلاج الكيميائي بعد الجراحات الموضعية، وعلاج الجروح والحالات المرتبطة بها والوقاية من التصاقات الأنسجة بعد الجراحة، ودعم وتوجيه نمو الخلايا في تطبيقات هندسة الأنسجة. وفي هذا الإطار، أثبتت الأبحاث على الألياف البلمرية النانوية بخصائصها الفريدة خلال العقد الماضي إمكانية استخدامها كأساس لكثير من التطبيقات الطبية الحيوية. ومن أهم هذه الخصائص ارتفاع نسبة المسامية واتساع مساحة السطح والقوة الميكانيكية إضافة إلى إمكانية توظيفها كنظام موصل موضعي للأدوية والمواد النشطة بيولوجيا والتحكم الزمني في انطلاقها.

الهدف من الرسالة

تهدف الرسالة إلى تطوير نوع جديد من الألياف البلمرية النانوية المغزولة كهربيا والمضادة للجراثيم دون زيادة المقاومة الجرثومية والقابلة للتنشيط الضوئي في التطبيقات الطبية الحيوية الموضعية وذلك للمساهمة في تحسين المردود العلاجي في هذه التطبيقات. اعتمد تحقيق هدف الرسالة على الجمع بين الخصائص التركيبية والوظيفية للألياف النانوية كنظام حامل لتوصيل الدواء ودعامة ميكانيكية لنمو الخلايا وغشاء حاجز لمنع التصاق الأنسجة بعد العمليات الجراحية وكذلك التأثيرات الحيوية المجتمعة للميثيلين الأزرق كمضاد للجراثيم دون زيادة مقاومتها ومحفز ضوئي قادر على تعزيز المفعول المضاد للجراثيم عند التعرض للضوء (وهو أساس ما يعرف بالعلاج الضوئي المضاد للجراثيم) إضافة إلى تأثيرات حيوية أخرى.

تقع الرسالة في أربعة فصول تتناول تطوير ألياف بلمرية نانوية وتوصيفها وتقييم استخدامها في الحد من التصاقات الأنسجة بعد العمليات الجراحية في نموذج الفئران وكمواد حيوية مضادة للجراثيم بالتعزيز الضوئي لعلاج الجروح الاستئصالية الملوثة في نموذج الفئران المثبطة المناعة.

الفصل الأول:

تطوير ألياف نانوية من عديد هيدروكسي البيوتيرات محملة بالميثيلين الأزرق للتطبيقات الطبية الحيوية

تناول هذا الفصل تطوير ألياف نانوية مصنعة بطريقة الغزل الكهربائي من بلمر عديد هيدروكسي البيوتيرات وتحميلها بالميثيلين الأزرق وذلك بغرض توظيف النسيج الليفي الناتج في تطبيقات طبية حيوية مختلفة. تم استخدام طريقة الغزل الكهربائي للمستحلب لتحضير الألياف نظرا لذوبانية الميثيلين الأزرق في الماء كما تم مزج عديد هيدروكسي البيوتيرات الكاره للماء مع عديد الإيثيلين جليكول ٤٠٠٠ المحب للماء للحصول على ألياف نانوية مقبولة من حيث الشكل والحجم وذات خصائص متباينة من حيث كفاءة تحميل ومعدل انطلاق المادة الفعالة والقدرة على امتصاص الماء. ولذلك فقد تم دراسة تأثير تركيب المستحلب وتركيز البلمر ونسبة التحميل الأولي للمادة الفعالة على خصائص الألياف المبينة عليه. تم توصيف الألياف باستخدام المجهر الإلكتروني الماسح وطرق التحليل الحراري التفاضلي والأشعة تحت الحمراء وتعيين نسبة كفاءة التحميل بالمادة الفعالة ومعدل انطلاقها من الألياف وكذلك سرعة تحلل الألياف معمليا. بينت النتائج أن متوسط قطر الألياف تراوح بين ٤٠٠ و ٦٠٠ نانومترا

وأنها تميزت في مجملها بكفاءة تحميل مرتفعة وصلت إلى ١٠٠٪ في بعض التركيبات. وبناء على هذه النتائج، تم اختيار نوعين من الألياف لمزيد من التوصيف هما الألياف النانوية المصنعة من عديد هيدروكسي البيوتيرات ومزيج عديد هيدروكسي البيوتيرات وعديد الإيثيلين جليكول بنسبة ٤٠/٦٠. يتميز النوع الأول بانطلاق أولي سريع نسبياً للميثيلين الأزرق وبطء التحلل في الماء وهو مناسب للتطبيقات الطبية الحيوية طويلة المدى نسبياً والتي تستلزم عدم التحلل السريع للنسيج الليفي مثل الخيوط الطبية والأغشية المانعة لالتصاق الأنسجة بعد عمليات البطن. أما النوع الثاني فهو مناسب للتطبيقات المضادة للجراثيم الأقصر مدى مثل علاج الجروح والتي تستلزم تحكماً زمنياً ثنائياً الطور في انطلاق المادة الفعالة بحيث يمكن السيطرة على العدوى الجرثومية مبكراً في الجرح مع استمرار هذه السيطرة طوال الفترة اللازمة لالتئام الجرح. وباختبار النشاط المضاد للجراثيم لهذين النوعين من الألياف معملياً باستخدام سلالتين بكتيريتين هما البكتريا العنقودية الذهبية المقاومة للميثيلين (MRSA) والبكتريا العنقودية الذهبية (*Staphylococcus aureus*)، تبين عدم تأثير النشاط المضاد للبكتيريا للميثيلين الأزرق بالتعرض لظروف الغزل الكهربائي للألياف (باستخدام طريقة الانتشار في الأجار) و قدرة الألياف المحملة بالميثيلين الأزرق على مقاومة البكتيريا (باستخدام تقنية العد).

خلص هذا الفصل إلى إمكانية استخدام ألياف عديد هيدروكسي البيوتيرات ومزيج عديد هيدروكسي البيوتيرات وعديد الإيثيلين جليكول النانوية المحملة بالميثيلين الأزرق في تطبيقات طبية حيوية مختلفة مضادة للجراثيم .

الفصل الثاني:

قدرة مواد حيوية مختارة من عديد هيدروكسي البيوتيرات للحد من التصاق الأنسجة في الفئران

تناول هذا الفصل دراسة قدرة الألياف النانوية المصنعة من بلمر عديد هيدروكسي البيوتيرات منفرداً أو من مزيج بلمري مكون من ذات البلمر مع عديد الإيثيلين جليكول ٤٠٠٠ والمحملة بمادة الميثيلين الأزرق كمادة مضادة للأكسدة والجراثيم، علي الحد من التصاق الأنسجة البريتونية بعد العمليات الجراحية وذلك باستخدام نموذج التصاق المعوي الأعور وجدار البطن في إناث الفئران. تم تقييم الالتصاقات المتكونة بعد الجراحة باستخدام مقياس متعارف عليه لتوصيفها من حيث درجة الانتشار والقوة المطلوبة لفصل الالتصاقات والخصائص التشريحية للأنسجة المتكونة. فضلاً عن ذلك، تم تقييم طبيعة التئام الأنسجة ما بعد الجراحة ودرجة تليف أنسجة الالتصاقات من خلال التحليل النسيجي لهذه الأنسجة. تشتمل الدراسة على جزئين. تم في الجزء الأول تقييم قدرة الألياف النانوية المحضرة من كل من عديد هيدروكسي البيوتيرات منفرداً ومن المزيج البلمري، المحملة بالميثيلين الأزرق بكمية تسمح بجرعة مقدارها ٢,٥ مجم/كجم، كأغشية مانعة للالتصاقات ما بعد الجراحة وذلك باستخدام عدد من المعالجات الضابطة. أظهرت النتائج قدرة أكبر للألياف النانوية المصنعة من عديد هيدروكسي البيوتيرات علي الحد من الالتصاقات البريتونية مقارنة بتلك المحضرة من المزيج البلمري. أعزى الفرق إلى ارتشاح عديد الإيثيلين جليكول القابل للذوبان في الماء مما يؤدي إلى زيادة مسامية الألياف وتسلل ونمو الخلايا داخلها وهو ما أكده فحص الألياف النانوية المستخرجة من التجويف البريتوني في نهاية الدراسة بواسطة المجهر الإلكتروني الماسح والذي أظهر زيادة في مسامية الألياف المحضرة من المزيج البلمري ونمو واضحاً للخلايا فيها مقارنة بنمو محدود للخلايا علي سطح ألياف عديد هيدروكسي البيوتيرات. أثبتت الدراسة أن تحميل الألياف محل الدراسة بالميثيلين الأزرق، ولاسيما الألياف المحضرة من المزيج البلمري والتي تسمح بانطلاق بالميثيلين الأزرق بمعدل أسرع يعزز نسبياً من قدرتها علي الحد من الالتصاقات مما يشير إلى أهمية توافر المادة الفعالة بتركيز موضعي كاف في المرحلة المبكرة بعد الجراحة. بينت نتائج الجزء الأول من الدراسة أن هناك حاجة لتحسين أداء المواد الحيوية المعتمدة على عديد هيدروكسي البيوتيرات كحاجز مانع للالتصاقات الأنسجة البريتونية وأن هذا

التحسين يتطلب استخدام حاجز ذي تركيب بلمري منخفض المسامية ولا يسمح بزيادة كبيرة في المسامية في الوسط البيولوجي (مما أدى إلى استبعاد المزيج البلمري) إضافة إلى زيادة في جرعة المثيلين الأزرق. وقد أخذت استنتاجات الجزء الأول من الدراسة في الاعتبار عند تصميم الجزء الثاني الذي تم الاعتماد فيه على أغشية من عديد هيدروكسي البيوتيرات مانعة للاتصاقات مكونة إما من ألياف نانوية مغزولة كهربيا أو أغشية غير ليفية ذات تركيب مماثل محضرة بطريقة الصب كما تم زيادة التحميل بالمثيلين الأزرق لإتاحة جرعة مقدارها ٢٠ مجم/كجم، جزء منها محمل سطحيا لضمان انطلاق سريع للمادة الفعالة، وذلك باستخدام التجارب الضابطة اللازمة. أظهرت نتائج الفحص بالمجهر الإلكتروني الماسح والفحص التشريحي للاتصاقات وتعيين عدد كرات الدم البيضاء في عينات من دم الفئران تفوقا ملحوظا للغشاء غير الليفي المحضر بالصب والمحمل بالمثيلين الأزرق في الحد من الالتصاقات البريتونية والالتهابات ما بعد الجراحة. وقد أرجع عدم نمو الخلايا على هذا الغشاء إلى ملاسة السطح وقلة المسامية وسرعة انطلاق المثيلين الأزرق. تشير النتائج إلى ضرورة إجراء المزيد من الدراسات لتقييم قدرة المواد الحيوية المعتمدة على الألياف النانوية مقارنة بالأغشية المصنوبة وذلك تحت نفس الظروف المعملية حيث أن النمط الشائع للدراسات المنشورة يعتمد على تقييم كل نوع على حدة.

الفصل الثالث:

ألياف نانوية مطلقة للمثيلين الأزرق كمادة حيوية محتملة لتطبيقات العلاج الضوئي المضاد للجراثيم

تناول هذا الفصل دراسة إمكانية تعزيز المفعول المضاد للجراثيم للألياف النانوية المحضرة بطريقة الغزل الكهربائي للبلمر المكون من مزيج من عديد هيدروكسي البيوتيرات وعديد الإيثيلين جليكول ٤٠٠٠ والمحملة بالمثيلين الأزرق كمحفز ضوئي وذلك عن طريق التحفيز الكيميائي الضوئي باستخدام الضوء الأحمر (٦٥٠ نانومتر باستخدام الباعث الضوئي الثنائي). أظهرت نتائج دراسات تقييم نفاذ الضوء من خلال مصفوفة الألياف البلمرية النانوية عدم شفافية هذه الألياف للضوء وضرورة أن يعتمد التحفيز الضوئي على الانطلاق المسبق للمثيلين الأزرق. وبناء على ذلك فقد تم تصميم الدراسة على استخدام ألياف نانوية تسمح بانطلاق المثيلين الأزرق بنمط ثنائي الطور يتسم بمعدلات إنطلاق أولية عالية، يمكن عن طريق التحفيز الضوئي المتزامن أن تؤدي إلى التثبيط الفوري المبكر لنمو الجراثيم على أن يسمح التحكم الزمني في الطور الثاني في انطلاق أبطء يؤدي إلى استمرار تأثير المثيلين الأزرق المضاد للبكتيريا في عدم وجود الضوء وذلك اعتمادا على حماية الألياف البلمرية للمثيلين الأزرق المحوصل وعدم تأثر ثباتيته الكيميائية بالتحفيز الضوئي. ولتحديد المدى الأمثل لقوة الضوء المطلوبة لتحفيز المثيلين الأزرق في محلول مائي، تم استخدام طريقة حمض البوليك كعامل كابح للأكسجين النشط الناتج عن التحفيز الضوئي. وقد وجد أن زيادة قوة الضوء فيما بين ٥٠ إلى ٣٠٠ جول/سم^٢ يؤدي إلى إنتاج المزيد من الأكسجين النشط مع عدم تأثر إنتاجه بزيادة قوة الضوء إلى ٤٠٠ جول/سم^٢. وبناء عليه تم استخدام قوة ضوء مقدارها ٥٠-٢٠٠ جول/سم^٢ في التجارب التالية.

وبدراسة النشاط المضاد للجراثيم لمحلول المثيلين الأزرق باستخدام سلالات البكتريا العنقودية الذهبية المقاومة للمسيثيلين (MRSA) والبكتريا العنقودية الذهبية (Staphylococcus aureus)، تبين أن التحفيز الضوئي (١٠٠ جول/سم^٢) يزيد من نشاط المثيلين الأزرق المضاد للجراثيم وتعتمد هذه الزيادة على تركيز المثيلين الأزرق ومدة الحضانه مع البكتيريا وقد أمكن القضاء على البكتيريا العنقودية الذهبية المقاومة للمسيثيلين (MRSA) تماما باستخدام محلول المثيلين الأزرق بتركيز ٥٠ مجم/مل ومدة حضانه لا تقل عن ١٥ دقيقة تسمح بانطلاق كمية كافية من المثيلين الأزرق. وباختبار نشاط الألياف النانوية المحملة بالمثيلين الأزرق المضاد للجراثيم، تبين أن التحفيز الضوئي (١٠٠ جول/سم^٢)

للمثيلين الأزرق بعد فترة حضانة ١٥ دقيقة لعينات الألياف في وجود البكتيريا قد أدى إلى القضاء تماما على بكتيريا الـ MRSA و الحد إلى درجة كبيرة من نمو البكتيريا العنقودية الذهبية (Staphylococcus aureus). كما بينت النتائج استمرار النشاط المضاد للجراثيم لفترة دراسة مدتها ٢٤ ساعة بعد التحفيز الضوئي مما يؤكد عدم استعادة البكتيريا لنشاطها وتأثير المثيلين الأزرق الممتد الإنطلاق.

خلص هذا الفصل إلى إثبات إمكانية التحفيز الضوئي للنشاط المضاد للبكتيريا للألياف النانوية المحضرة بطريقة الغزل الكهربائي للبلمر المكون من مزيج من عديد هيدروكسي البيوتيرات وعديد الإيثيلين جليكول ٤٠٠٠ والمحملة بالمثيلين الأزرق كمحفز ضوئي ومضاد بكتيري. وبهذا تمثل هذه الألياف قاعدة لنوع جديد من الألياف النانوية تعتمد آلية تحفيزها ضوئيا على انطلاق المحفز الضوئي. تتميز هذه الألياف المعتمدة بحماية المحفز الضوئي المحوصل بداخلها من التعرض للضوء في غير أوقات التحفيز المطلوب كما أنها تسمح بمفعول سريع مضاد للبكتيريا بمجرد التحفيز الضوئي ومفعول إضافي ممتد مرتبط بالانطلاق المنضبط للمثيلين الأزرق كمضاد بكتيري. ومن المتوقع أن تجعل هذه الخصائص من الألياف النانوية موضوع الدراسة والتي تجمع بين الخصائص البنائية والوظيفية المتعددة للألياف النانوية وخصائص المثيلين الأزرق كمادة فعالة متعددة التأثيرات الحيوية، مادة حيوية مفيدة في علاج الجروح الملوثة وهو موضوع الفصل الرابع.

الفصل الرابع:

ألياف نانوية مطلقة للمثيلين الأزرق للعلاج الضوئي المضاد للجراثيم للجروح الملوثة في الفئران المثبطة المناعة

بينت نتائج الفصول السابقة أن الألياف النانوية المصنعة من مزيج عديد هيدروكسي البيوتيرات وعديد الإيثيلين جليكول ٤٠٠٠ و المحملة بالمثيلين الأزرق تتسم بالخصائص المطلوبة لتعزيز إلتئام الجروح وذلك بفضل خواصها المحبة للماء وقدرتها الجيدة على امتصاص السوائل وتسهيل نمو الخلايا عليها، إضافة إلى إمكانية تعزيز المفعول المضاد للبكتيريا من حيث الشدة والسرعة بالتحفيز الضوئي. تم اختبار هذه الألياف في علاج الجروح الاستئصالية المصابة بالبكتيريا في نموذج الفئران المثبطة المناعة، والتي تشكل نموذجا متحديا من الجروح. تم إحداث الجروح المصابة بالبكتيريا المكورة العنقودية الذهبية في نموذج الفئران ذوات المناعة المثبطة بواسطة السيكلوسبورين-أ. وقد تمت إضاءة الجروح بواسطة الضوء الأحمر ذو الطول الموجي ٦٥٠ نانومتر بعد إطلاق كمية مناسبة من المثيلين الأزرق من المصفوفات الليفية. تم تقييم خصائص التئام الجروح بواسطة الألياف عن طريق الفحص الشكلي للجروح وقياس أبعادها والفحص الميكروبيولوجي لمسحات من الجروح والفحص النسيجي لعملية الإلتئام وذلك بإستخدام المعالجات الضابطة اللازمة لتفسير النتائج. أظهرت النتائج قدرة الألياف موضوع الدراسة على تعزيز التئام الجروح ولاسيما بتكرار تعريض الجروح للضوء. أدى العلاج الضوئي المضاد للجراثيم على هذا النحو بإسراع عملية الإلتئام والقضاء على البكتيريا المعدية وتحسين جودة الإلتئام نظرا لعدم تكوين ندبة وعودة نمو الشعر. كما تم إستخدام تقنية تفاعل البوليمراز المتسلسل للكشف جينات كل من VEGF, PDGF, COX-2, TNF- α . أظهرت نتائج الدراسة مجتمعة أن إستخدام الألياف النانوية موضوع الدراسة كمادة حيوية لعلاج الجروح مصحوبا بالتحفيز الضوئي المضاد للجراثيم يعد تقنية مزدوجة جديدة فعالة في علاج الجروح صعبة الإلتئام. تتميز هذه التقنية على العلاج التقليدي بواسطة المضادات الحيوية بعدم تطویرسلالات جرثومية مقاومة للعلاج وإمكانية تطویرها لزيادة فعاليتها.

الخلاصة

تم في هذه الرسالة تقديم مواد حيوية معتمدة أساسا على بلمر عديد هيدروكي البيوتيرات وهي ألياف نانوية كارهة للماء مصنعة من عديد هيدروكي البيوتيرات وأخرى أكثرها حبا للماء مصنعة من المزيج البلمري المكون من هذا البلمر وعديد الإثيلين جليكول ٤٠٠٠ وهي ألياف متعددة الوظائف مغزولة كهربيا وذلك بالإضتفة إلى أغشية من عديد هيدروكي البيوتيرات جميعها محملة بمادة المثيلين الأزرق كصيغ مضاد للجراثيم ومضاد للأكسدة ومحفز ضوئي وذلك للإستخدام في تطبيقات حيوية مختلفة. يعتمد إستخدام هذه المواد على خواصها الصيدلانية ولا سيما نمط انطلاق المادة الفعالة منها وتفاعلها مع الخلايا. أمكن إستخدام ألياف عديد هيدروكسي البيوتيرات بطيئة التحلل بعد تعديل مواصفاتها في الحد من الالتصاقات البريتونية بعد الجراحة في الفئران إلا أن كفاءتها كانت أقل من أغشية غير ليفية بنفس التكوين محضرة بطريق الصب. كما أمكن إستخدام ألياف نانوية محضرة من المزيج البلمري محملة بالمثيلين الأزرق مع طريقة التحفيز الضوئي كتقنية مزدوجة جديدة لعلاج الجروح تعتمد على انطلاق المحفز وإثبات فعالية هذه التقنية في علاج الجروح صعبة الالتئام في الفئران. تعتبر المواد الحيوية المقدمة في هذه الرسالة إضافة هامة للتطبيقات الطبية الحيوية المضادة للجراثيم لا تؤدي إلى تكوين سلالات مقاومة من الجراثيم يمكن أن تكون بديلا لإستخدام الأنظمة المعتمدة على المضادات الحيوية مما يساعد في ترشيد إستخدام المضادات الحيوية.

إقرار

أقر أنه لا يوجد أى جزء من هذا العمل قد سبق تقديمه لنيل درجة أخرى فى هذه الجامعة
أو أى معهد أو مؤسسة تعليمية أخرى

نسمة السيد أحمد أحمد إبراهيم

التوقيع

أ.د/ لبيبة خليل الخردجي
أستاذ متفرغ بقسم الصيدلانيات
كلية الصيدلة - جامعة الإسكندرية

د/ سالى جلال عبد الحليم
مدرس بقسم الصيدلانيات
كلية الصيدلة - جامعة الإسكندرية



جامعة الإسكندرية

كلية الصيدلة

قسم الصيدلانيات

" دراسة صيدلانية لأنظمة توصيل بلمرية لتطبيقات طبية حيوية موضعية "

رسالة مقدمة من

نسمة السيد أحمد أحمد إبراهيم

التوقيع

لجنة الحكم والمناقشة

أ.د/ لبيبة خليل الخردجي

أ.د/ أميمة نعيم الجزايرلى

أ.د/ مها فاضل محمد على



جامعة الإسكندرية

كلية الصيدلة

قسم الصيدلانيات

" دراسة صيدلانية لأنظمة توصيل بلمرية لتطبيقات طبية حيوية موضعية "

رسالة مقدمة

لقسم الصيدلانيات – كلية الصيدلة – جامعة الاسكندرية

كجزء من متطلبات درجة

الماجستير

فى

العلوم الصيدلانية (الصيدلانيات)

من

نسمة السيد أحمد أحمد إبراهيم

بكالوريوس فى العلوم الصيدلانية ٢٠٠٧

كلية الصيدلة

جامعة الاسكندرية

يناير ٢٠١٣